Details of Drug-Metabolizing Enzyme (DME)

General Information of DME (ID: DME0009)
DME Name Cytochrome P450 2D6 (CYP2D6), Homo sapiens
Synonyms Cytochrome P450 family 2 subfamily D member 6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; CYP2D6; CYP2DL1; CYPIID6
Gene Name CYP2D6
UniProt ID
CP2D6_HUMAN
Gene ID
1565
EC Number    EC: 1.14.14.1     (Click to Show/Hide the Complete EC Tree)
Oxidoreductase
Oxygen paired donor oxidoreductase
Flavin/flavoprotein donor oxidoreductase
EC: 1.14.14.1
Lineage    Species: Homo sapiens     (Click to Show/Hide the Complete Species Lineage)
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Interactome
(loading-time for this interactome depdends on the speed of web connection)
       Interactions between Microbiome and DME (MICBIO)                       
Jump to Detailed Interactome Data                      
       Interactions between Xenobiotics and DME (XEOTIC)                      
Jump to Detailed Interactome Data                      
       Interactions between Host Protein and DME (HOSPPI)                     
Jump to Detailed Interactome Data                      
      Click to Show/Hide the Molecular/Functional Data (Sequence/Structure/Pathway/Function) of This DME
Sequence
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR
Structure
3TBG ; 3TDA ; 4WNT ; 4WNU ; 4WNV ; 4WNW ; 4XRY ; 4XRZ ; 5TFT
Pathway Drug metabolism - cytochrome P450 (hsa00982 )
Endocrine resistance (hsa01522 )
Metabolism of xenobiotics by cytochrome P450 (hsa00980 )
Serotonergic synapse (hsa04726 )
Function This enzyme is involved in the metabolism of fatty acids, steroids and retinoids. It catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA). It also metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 20-hydroxyeicosatetraenoic acid ethanolamide (20-HETE-EA) and 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs). In addition, it catalyzes the hydroxylation of carbon-hydrogen bonds and metabolizes cholesterol toward 25- hydroxycholesterol. It catalyzes the oxidative transformations of all-trans retinol to all-trans retina and also involved in the oxidative metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Full List of Drug(s) Metabolized by This DME
      Drugs Approved by FDA Click to Show/Hide the Full List of Drugs:      287 Drugs
Bambuterol
 Drug Info Approved Asthma ICD11: CA23 [1]
Cobicistat
 Drug Info Approved Human immunodeficiency virus infection ICD11: 1C60 [2]
Bupropion
 Drug Info Approved Nicotine dependence ICD11: 6C4A [3]
Tamoxifen citrate
 Drug Info Approved Breast cancer ICD11: 2C60 [4]
Yn-968D1
 Drug Info Approved Breast cancer ICD11: 2C60-2C6Y [5]
Erlotinib hydrochloride
 Drug Info Approved Lung cancer ICD11: 2C25 [6]
Idelalisib
 Drug Info Approved Chronic lymphocytic leukaemia ICD11: 2A82 [7]
Estrone
 Drug Info Approved Menopausal disorder ICD11: GA30 [8]
Methylphenidate
 Drug Info Approved Attention deficit hyperactivity disorder ICD11: 6A05 [9]
Nicotine
 Drug Info Approved Nicotine dependence ICD11: 6C4A [10]
Cocaine
 Drug Info Approved Anaesthesia ICD11: 8E22 [11]
Pimavanserin
 Drug Info Approved Parkinsonism ICD11: 8A00 [12]
Bortezomib
 Drug Info Approved Breast cancer ICD11: 2C60 [13]
Delavirdine mesylate
 Drug Info Approved Human immunodeficiency virus infection ICD11: 1C60 [14]
Hydrocodone
 Drug Info Approved Pain ICD11: MG30-MG3Z [15]
Pindolol
 Drug Info Approved Hypertension ICD11: BA00-BA04 [16]
Antazoline
 Drug Info Approved Nasal congestion ICD11: MD11 [17]
Galantamine hydrobromide
 Drug Info Approved Alzheimer disease ICD11: 8A20 [18]
Ibrutinib
 Drug Info Approved Mantle cell lymphoma ICD11: 2A85 [19]
Ketoconazole
 Drug Info Approved Dermatophytosis ICD11: 1F28 [20]
Metoclopramide hydrochloride
 Drug Info Approved Functional nausea/vomiting ICD11: DD90 [21]
Primaquine
 Drug Info Approved Malaria ICD11: 1F40 [22]
Progesterone
 Drug Info Approved Premature labour ICD11: JB00 [23]
Almogran
 Drug Info Approved Migraine ICD11: 8A80 [24]
Almogran
 Drug Info Approved Migraine ICD11: 8A80 [25], [26]
Imatinib mesylate
 Drug Info Approved Chronic myelogenous leukaemia ICD11: 2A20 [13]
Levobunolol
 Drug Info Approved Glaucoma ICD11: 9C61 [27]
Levodopa
 Drug Info Approved Parkinsonism ICD11: 8A00 [28]
Lidocaine
 Drug Info Approved Anaesthesia ICD11: 8E22 [29]
Cannabidiol
 Drug Info Approved Lennox-Gastaut syndrome ICD11: 8A62 [30]
Capsaicin
 Drug Info Approved Herpes zoster ICD11: 1E91 [31]
Clomipramine hydrochloride
 Drug Info Approved Obsessive-compulsive disorder ICD11: 6B20 [32]
Doxazosin
 Drug Info Approved Essential hypertension ICD11: BA00 [33]
Lapatinib ditosylate
 Drug Info Approved Breast cancer ICD11: 2C60 [6]
Pitavastatin
 Drug Info Approved Hypertriglyceridaemia ICD11: 5C80 [34]
Ticlopidine
 Drug Info Approved Cerebral stroke ICD11: 8B11 [35]
Tipranavir
 Drug Info Approved Human immunodeficiency virus infection ICD11: 1C60 [36]
Almotriptan malate
 Drug Info Approved Migraine ICD11: 8A80 [25]
Asenapine maleate
 Drug Info Approved Schizophrenia ICD11: 6A20 [37]
Betaxolol
 Drug Info Approved Essential hypertension ICD11: BA00 [38]
Bupivacaine hydrochloride
 Drug Info Approved Anaesthesia ICD11: 8E22 [39]
Clomipramine
 Drug Info Approved Depression ICD11: 6A70-6A7Z [40]
Clomipramine
 Drug Info Approved Depression ICD11: 6A70-6A7Z [32], [41], [42]
Cyclobenzaprine
 Drug Info Approved Depression ICD11: 6A71 [43]
Duloxetine hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [44]
Labetalol
 Drug Info Approved Essential hypertension ICD11: BA00 [45]
Mirabegron
 Drug Info Approved Overactive bladder ICD11: GC50 [46]
Oxycodone hydrochloride
 Drug Info Approved Anaesthesia ICD11: 8E22 [47]
Oxymorphone
 Drug Info Approved Anaesthesia ICD11: 8E22 [48]
Ranolazine
 Drug Info Approved Angina pectoris ICD11: BA40 [49]
Tacrine hydrochloride
 Drug Info Approved Alzheimer disease ICD11: 8A20 [24]
Trabectedin
 Drug Info Approved Leiomyosarcoma ICD11: 2B58 [50]
Clomiphene citrate
 Drug Info Approved Female infertility ICD11: GA31 [51]
Clomiphene citrate
 Drug Info Approved Female infertility ICD11: GA31 [52]
Dopamine hydrochloride
 Drug Info Approved Parkinsonism ICD11: 8A00 [53]
Fluvoxamine maleate
 Drug Info Approved Obsessive-compulsive disorder ICD11: 6B20 [54]
Halothane
 Drug Info Approved Anaesthesia ICD11: 8E22 [55]
Hydrocodone bitartrate
 Drug Info Approved Neuropathic pain ICD11: 8E43 [56]
Indinavir sulfate
 Drug Info Approved Human immunodeficiency virus infection ICD11: 1C60 [57]
Panobinostat lactate
 Drug Info Approved Multiple myeloma ICD11: 2A83 [58]
Quinine sulfate
 Drug Info Approved Malaria ICD11: 1F40 [59]
Remdesivir
 Drug Info Approved Coronavirus Disease 2019 (COVID-19) ICD11: 1D6Y [60]
Tamsulosin
 Drug Info Approved Prostatic hyperplasia ICD11: GA90 [61]
Tamsulosin
 Drug Info Approved Prostatic hyperplasia ICD11: GA90 [62]
Brexpiprazole
 Drug Info Approved Bipolar disorder ICD11: 6A60 [63]
Caffeine
 Drug Info Approved Orthostatic hypotension ICD11: BA21 [64]
Carvedilol
 Drug Info Approved Congestive heart failure ICD11: BD10 [13]
Deutetrabenazine
 Drug Info Approved Huntington disease ICD11: 8A01 [65]
Dextromethorphan hydrobromide
 Drug Info Approved Atherosclerosis ICD11: BA80 [66]
Doxepin hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [67]
Eliglustat tartrate
 Drug Info Approved Gaucher disease ICD11: 5C56 [68]
Formoterol
 Drug Info Approved Asthma ICD11: CA23 [69]
Haloperidol decanoate
 Drug Info Approved Agitation/aggression ICD11: 6D86 [70]
Lasofoxifene
 Drug Info Approved Osteoporosis ICD11: FB83 [71]
Lasofoxifene
 Drug Info Approved Osteoporosis ICD11: FB83 [72]
Lorcaserin
 Drug Info Approved Obesity ICD11: 5B81 [73]
Nateglinide
 Drug Info Approved Diabetes mellitus ICD11: 5A10 [74]
Nevirapine
 Drug Info Approved Human immunodeficiency virus infection ICD11: 1C60 [75]
Ondansetron
 Drug Info Approved Gastritis ICD11: DA42 [76]
Pomalidomide
 Drug Info Approved Breast cancer ICD11: 2C60 [77]
Propafenone hydrochloride
 Drug Info Approved Ventricular tachyarrhythmia ICD11: BC71 [78]
Propranolol hydrochloride
 Drug Info Approved Migraine ICD11: 8A80 [79]
Trazodone hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [80]
Umeclidinium bromide
 Drug Info Approved Chronic obstructive pulmonary disease ICD11: CA22 [81]
Amitriptyline hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [82]
Amprenavir
 Drug Info Approved Human immunodeficiency virus infection ICD11: 1C60 [83]
Artemether
 Drug Info Approved Malaria ICD11: 1F40 [84]
Atomoxetine hydrochloride
 Drug Info Approved Attention deficit hyperactivity disorder ICD11: 6A05 [85]
Benzatropine
 Drug Info Approved Agitation/aggression ICD11: 6D86 [86]
Betrixaban
 Drug Info Approved Venous thromboembolism ICD11: BD72 [87]
Bromfenac
 Drug Info Approved Cataract ICD11: 9B10 [88]
Buspirone
 Drug Info Approved Anxiety disorder ICD11: 6B00 [89]
Captopril
 Drug Info Approved Essential hypertension ICD11: BA00 [55]
Cevimeline hydrochloride
 Drug Info Approved Sjogren syndrome ICD11: 4A43 [90]
Cinacalcet hydrochloride
 Drug Info Approved Hyperparathyroidism ICD11: 5A51 [91]
Codeine
 Drug Info Approved Anaesthesia ICD11: 8E22 [66]
Darifenacin hydrobromide
 Drug Info Approved Overactive bladder ICD11: GC50 [92]
Desvenlafaxine succinate
 Drug Info Approved Depression ICD11: 6A71 [93]
Diltiazem hydrochloride
 Drug Info Approved Essential hypertension ICD11: BA00 [94]
Donepezil hydrochloride
 Drug Info Approved Alzheimer disease ICD11: 8A20 [95]
Doxorubicin
 Drug Info Approved Breast cancer ICD11: 2C60 [96]
Dronedarone hydrochloride
 Drug Info Approved Atrial fibrillation ICD11: BC81 [97]
Exjade
 Drug Info Approved Hyperphosphatemia ICD11: 5C64 [98]
Fluoxetine hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [99]
Fluvastatin sodium
 Drug Info Approved Hypertriglyceridaemia ICD11: 5C80 [100]
Imipramine hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [101]
Indomethacin
 Drug Info Approved Rheumatoid arthritis ICD11: FA20 [102]
Istradefylline
 Drug Info Approved Parkinsonism ICD11: 8A00 [103]
Lesinurad
 Drug Info Approved Uncontrolled gout ICD11: FA25 [104]
Letermovir
 Drug Info Approved Cytomegalovirus infection ICD11: 1D82 [105]
Levomepromazine
 Drug Info Approved Insomnia ICD11: 7A00 [106]
Lisdexamfetamine
 Drug Info Approved Attention deficit hyperactivity disorder ICD11: 6A05 [107]
Metoprolol succinate
 Drug Info Approved Essential hypertension ICD11: BA00 [108]
Metoprolol tartrate
 Drug Info Approved Angina pectoris ICD11: BA40 [108]
Morphine
 Drug Info Approved Anaesthesia ICD11: 8E22 [109]
Nefazodone
 Drug Info Approved Depression ICD11: 6A71 [110]
Olanzapine
 Drug Info Approved Schizophrenia ICD11: 6A20 [111]
Phenytoin
 Drug Info Approved Epilepsy ICD11: 8A60 [40]
Quinidine
 Drug Info Approved Ventricular tachyarrhythmia ICD11: BC71 [112]
Revefenacin
 Drug Info Approved Chronic obstructive pulmonary disease ICD11: CA22 [113]
Ropivacaine hydrochloride
 Drug Info Approved Anaesthesia ICD11: 8E22 [55]
Rucaparib
 Drug Info Approved Ovarian cancer ICD11: 2C73 [114]
Simvastatin
 Drug Info Approved Dyslipidaemia ICD11: 5C81 [115]
Tapentadol
 Drug Info Approved Neuropathic pain ICD11: 8E43 [116]
Tegaserod
 Drug Info Approved Irritable bowel syndrome ICD11: DD91 [117]
Zolpidem tartrate
 Drug Info Approved Insomnia ICD11: 7A00 [118]
Amiodarone hydrochloride
 Drug Info Approved Ventricular tachyarrhythmia ICD11: BC71 [119]
Amoxapine
 Drug Info Approved Depression ICD11: 6A71 [120]
Azelastine
 Drug Info Approved Allergic rhinitis ICD11: CA08 [121]
Buprenorphine hydrochloride
 Drug Info Approved Anaesthesia ICD11: 8E22 [122]
Chlorpromazine hydrochloride
 Drug Info Approved Schizophrenia ICD11: 6A20 [70]
Citalopram hydrobromide
 Drug Info Approved Depression ICD11: 6A71 [123]
Clonidine
 Drug Info Approved Essential hypertension ICD11: BA00 [124]
Clozapine
 Drug Info Approved Schizophrenia ICD11: 6A20 [125]
Diphenhydramine
 Drug Info Approved Meniere disease ICD11: AB31 [126]
Dolasetron mesylate
 Drug Info Approved Functional nausea/vomiting ICD11: DD90 [127]
Ethosuximide
 Drug Info Approved Epilepsy ICD11: 8A60 [128]
Fingolimod
 Drug Info Approved Multiple sclerosis ICD11: 8A40 [129]
Fingolimod hydrochloride
 Drug Info Approved Multiple sclerosis ICD11: 8A40 [129]
Loxapine succinate
 Drug Info Approved Schizophrenia ICD11: 6A20 [130]
Metamfetamine
 Drug Info Approved Attention deficit hyperactivity disorder ICD11: 6A05 [131]
Methamphetamine hydrochloride
 Drug Info Approved Attention deficit hyperactivity disorder ICD11: 6A05 [131]
Mirtazapine
 Drug Info Approved Depression ICD11: 6A71 [132]
Nalbuphine
 Drug Info Approved Pain ICD11: MG30-MG3Z [133]
Oxycodone
 Drug Info Approved Pain ICD11: MG30-MG3Z [134]
Paroxetine hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [135]
Pazopanib
 Drug Info Approved Renal cell carcinoma ICD11: 2C90 [136]
Perphenazine
 Drug Info Approved Schizophrenia ICD11: 6A20 [70]
Pimozide
 Drug Info Approved Schizophrenia ICD11: 6A20 [137]
Ponatinib hydrochloride
 Drug Info Approved Acute lymphoblastic leukemia ICD11: 2B33 [138]
Pralsetinib
 Drug Info Approved Lung cancer ICD11: 2C25 [139]
Pralsetinib
 Drug Info Approved Lung cancer ICD11: 2C25 [140]
Prochlorperazine
 Drug Info Approved Functional nausea/vomiting ICD11: DD90 [141]
Propofol
 Drug Info Approved Anaesthesia ICD11: 8E22 [142]
Quetiapine fumarate
 Drug Info Approved Schizophrenia ICD11: 6A20 [143]
Ritonavir
 Drug Info Approved Human immunodeficiency virus infection ICD11: 1C60 [144]
Solifenacin succinate
 Drug Info Approved Overactive bladder ICD11: GC50 [145]
Sumatriptan
 Drug Info Approved Migraine ICD11: 8A80 [146]
Tandospirone
 Drug Info Approved Anxiety disorder ICD11: 6B00-6B0Z [147]
Tasimelteon
 Drug Info Approved Insomnia ICD11: 7A00 [148]
Theophylline
 Drug Info Approved Chronic obstructive pulmonary disease ICD11: CA22 [149]
Thioridazine
 Drug Info Approved Schizophrenia ICD11: 6A20 [150]
Tramadol hydrochloride
 Drug Info Approved Neuropathic pain ICD11: 8E43 [151]
Triclosan
 Drug Info Approved Malaria ICD11: 1F40-1F45 [152]
Venlafaxine hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [153]
Vilazodone hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [154]
Vortioxetine hydrobromide
 Drug Info Approved Depression ICD11: 6A71 [155]
Acetaminophen
 Drug Info Approved Anaesthesia ICD11: 8E22 [156]
Amphetamine
 Drug Info Approved Attention deficit hyperactivity disorder ICD11: 6A05 [157]
Aripiprazole lauroxil
 Drug Info Approved Schizophrenia ICD11: 6A20 [158]
Benzocaine
 Drug Info Approved Anaesthesia ICD11: 9A76-9A78 [159]
Binimetinib
 Drug Info Approved Melanoma ICD11: 2C30 [160]
Chlorpheniramine
 Drug Info Approved Allergic rhinitis ICD11: CA08 [161]
Ciclesonide
 Drug Info Approved Asthma ICD11: CA23 [162]
Dapagliflozin
 Drug Info Approved Diabetes mellitus ICD11: 5A10 [163]
Desloratadine
 Drug Info Approved Allergic rhinitis ICD11: CA08 [164]
Dutasteride
 Drug Info Approved Prostatic hyperplasia ICD11: GA90 [44]
Fesoterodine
 Drug Info Approved Overactive bladder ICD11: GC50 [165]
Gefitinib
 Drug Info Approved Lung cancer ICD11: 2C25 [166]
Iloperidone
 Drug Info Approved Schizophrenia ICD11: 6A20 [167]
Levallorphan
 Drug Info Approved Narcotic depression ICD11: 6A70-6A7Z [168]
Levomethadyl acetate hydrochloride
 Drug Info Approved Opiate dependence ICD11: 6C43 [169]
Levomilnacipran
 Drug Info Approved Depression ICD11: 6A71 [170]
Loperamide hydrochloride
 Drug Info Approved Irritable bowel syndrome ICD11: DD91 [171]
Lovastatin
 Drug Info Approved Hypertriglyceridaemia ICD11: 5C80 [172]
Maprotiline hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [173]
Meclizine
 Drug Info Approved Functional nausea/vomiting ICD11: DD90 [174]
Methadone
 Drug Info Approved Anaesthesia ICD11: 8E22 [175]
Methyldopa
 Drug Info Approved Essential hypertension ICD11: BA00 [176]
Mexiletine hydrochloride
 Drug Info Approved Ventricular tachyarrhythmia ICD11: BC71 [177]
Midodrine
 Drug Info Approved Orthostatic hypotension ICD11: BA21 [178]
Palonosetron hydrochloride
 Drug Info Approved Functional nausea/vomiting ICD11: DD90 [76]
Pitolisant
 Drug Info Approved Excessive daytime sleepiness ICD11: MG42 [179]
Procainamide hydrochloride
 Drug Info Approved Ventricular tachyarrhythmia ICD11: BC71 [180]
Promethazine
 Drug Info Approved Functional nausea/vomiting ICD11: DD90 [178]
Ranitidine
 Drug Info Approved Peptic ulcer ICD11: DA61 [181]
Tapinarof
 Drug Info Approved Discovery agent ICD: N.A. [182]
Timolol maleate
 Drug Info Approved Essential hypertension ICD11: BA00 [183]
Tolterodine tartrate
 Drug Info Approved Overactive bladder ICD11: GC50 [184]
Vinorelbine tartrate
 Drug Info Approved Lung cancer ICD11: 2C25 [96]
Zidovudine
 Drug Info Approved Human immunodeficiency virus infection ICD11: 1C60 [55], [185]
Acebutolol
 Drug Info Approved Essential hypertension ICD11: BA00 [27]
Alogliptin
 Drug Info Approved Diabetes mellitus ICD11: 5A10 [186]
Arformoterol
 Drug Info Approved Chronic obstructive pulmonary disease ICD11: CA22 [187]
Azilsartan
 Drug Info Approved Hypertension ICD11: BA00-BA04 [188], [189]
Cariprazine hydrochloride
 Drug Info Approved Bipolar disorder ICD11: 6A60 [190]
Carteolol hydrochloride
 Drug Info Approved Glaucoma ICD11: 9C61 [191]
Celecoxib
 Drug Info Approved Rheumatoid arthritis ICD11: FA20 [192]
Cilostazol
 Drug Info Approved Arteriosclerosis obliterans ICD11: BD40 [193]
Clofibrate
 Drug Info Approved Hypertriglyceridaemia ICD11: 5C80 [194]
Dexchlorpheniramine maleate
 Drug Info Approved Rheumatoid arthritis ICD11: FA20 [161]
Dextroamphetamine
 Drug Info Approved Narcolepsy ICD11: 7A20 [157]
Eletriptan hydrobromide
 Drug Info Approved Migraine ICD11: 8A80 [195]
Escitalopram
 Drug Info Approved Depression ICD11: 6A71 [196]
Esmolol
 Drug Info Approved Atrial fibrillation ICD11: BC81 [27]
Flecainide acetate
 Drug Info Approved Ventricular tachyarrhythmia ICD11: BC71 [197]
Flibanserin
 Drug Info Approved Inhibited sexual desire ICD11: HA00 [198]
Fluvoxamine
 Drug Info Approved Depression ICD11: 6A70-6A7Z [199]
Hydromorphone
 Drug Info Approved Anaesthesia ICD11: 8E22 [200]
Iclaprim
 Drug Info Approved Methicillin-resistant staphylococcus infection ICD11: 1D01 [201]
Loratadine
 Drug Info Approved Allergic rhinitis ICD11: CA08 [202]
Mephenytoin
 Drug Info Approved Epilepsy ICD11: 8A60 [203]
Nicardipine hydrochloride
 Drug Info Approved Essential hypertension ICD11: BA00 [204]
Nifedipine
 Drug Info Approved Angina pectoris ICD11: BA40 [205]
Oxamniquine
 Drug Info Approved Schistosomiasis ICD11: 1F86 [206]
Paliperidone
 Drug Info Approved Bipolar disorder ICD11: 6A60 [207]
Penbutolol
 Drug Info Approved Essential hypertension ICD11: BA00 [27]
Pentamidine isethionate
 Drug Info Approved Pneumocystis pneumonia ICD11: CA40 [22]
Phenmetrazine
 Drug Info Approved Obesity ICD11: 5B80-5B81 [208]
Selegiline
 Drug Info Approved Major depressive disorder ICD11: 6A70-6A7Z [209]
Selegiline hydrochloride
 Drug Info Approved Parkinsonism ICD11: 8A00 [210]
Sertraline hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [211]
Sildenafil citrate
 Drug Info Approved Erectile dysfunction ICD11: HA01 [13]
Tetrabenazine
 Drug Info Approved Huntington disease ICD11: 8A01 [212]
Tiotropium
 Drug Info Approved Chronic obstructive pulmonary disease ICD11: CA22 [213]
Tiotropium Bromide
 Drug Info Approved Chronic obstructive pulmonary disease ICD11: CA22 [214]
Triclabendazole
 Drug Info Approved Fascioliasis ICD11: 1F82 [215]
Trimipramine
 Drug Info Approved Depression ICD11: 6A71 [216]
Ulipristal
 Drug Info Approved Contraception ICD11: JA65 [217]
Umeclidinium
 Drug Info Approved Chronic obstructive pulmonary disease ICD11: CA22 [218]
Umeclidinium
 Drug Info Approved Chronic obstructive pulmonary disease ICD11: CA22 [219]
Valbenazine
 Drug Info Approved Dyskinesia ICD11: 8A02 [220]
Benzyl alcohol
 Drug Info Approved Pediculosis ICD11: 1G00 [221]
Bisoprolol
 Drug Info Approved Essential hypertension ICD11: BA00 [222]
Chloroquine
 Drug Info Approved Malaria ICD11: 1F40 [223]
Chloroquine
 Drug Info Approved Malaria ICD11: 1F40 [224]
Chlorzoxazone
 Drug Info Approved Anaesthesia ICD11: 8E22 [225]
Clevidipine
 Drug Info Approved Essential hypertension ICD11: BA00 [226]
Dacomitinib
 Drug Info Approved Lung cancer ICD11: 2C25 [227]
Desipramine
 Drug Info Approved Attention deficit hyperactivity disorder ICD11: 6A05 [228]
Encorafenib
 Drug Info Approved Melanoma ICD11: 2C30 [229]
Epinastine
 Drug Info Approved Conjunctivitis ICD11: 9A60 [230]
Fluphenazine decanoate
 Drug Info Approved Schizophrenia ICD11: 6A20 [125]
Fluphenazine enanthate
 Drug Info Approved Schizophrenia ICD11: 6A20 [125]
Glycopyrrolate
 Drug Info Approved Chronic obstructive pulmonary disease ICD11: CA22 [231]
Halofantrine
 Drug Info Approved Malaria ICD11: 1F40 [223]
Hydrogen peroxide
 Drug Info Approved Emphysema ICD11: CA21 [232]
Ibudilast
 Drug Info Approved Castleman's disease ICD11: 4B2Y [233]
Idarubicin
 Drug Info Approved Acute myeloid leukaemia ICD11: 2A60 [234]
Methyprylon
 Drug Info Approved Insomnia ICD11: 7A00 [235]
Metipranolol
 Drug Info Approved Glaucoma ICD11: 9C61 [27]
Nebivolol hydrochloride
 Drug Info Approved Pulmonary hypertension ICD11: BB01 [236]
Nortriptyline hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [237]
Pachycarpine
 Drug Info Approved Postpartum haemorrhage ICD11: JA43 [238]
Piperazine
 Drug Info Approved Ascariasis ICD11: 1F62 [239]
Prinomastat
 Drug Info Approved Lung cancer ICD11: 2C25 [240]
Rifampicin
 Drug Info Approved Osteoporosis ICD11: FB83 [241]
Ripretinib
 Drug Info Approved Gastrointestinal stromal tumour ICD11: 2B5B [242]
Risperidone
 Drug Info Approved Schizophrenia ICD11: 6A20 [243]
Sevoflurane
 Drug Info Approved Anaesthesia ICD11: 8E22 [244]
Tafenoquine
 Drug Info Approved Malaria ICD11: 1F40 [245]
Tilidine
 Drug Info Approved Pain ICD11: MG30-MG3Z [246]
Vinblastine sulfate
 Drug Info Approved Breast cancer ICD11: 2C60 [96]
Zalcitabine
 Drug Info Approved Human immunodeficiency virus infection ICD11: 1C60 [247]
Bepridil hydrochloride
 Drug Info Approved Angina pectoris ICD11: BA40 [248]
Cefalexin
 Drug Info Approved Acute otitis media ICD11: AB00 [249]
Elagolix sodium
 Drug Info Approved Endometriosis ICD11: GA10 [250]
Levobetaxolol
 Drug Info Approved Glaucoma ICD11: 9C61 [27]
Mesoridazine
 Drug Info Approved Schizophrenia ICD11: 6A20 [150]
Methoxyflurane
 Drug Info Approved Anaesthesia ICD11: 8E22 [251]
Rivastigmine
 Drug Info Approved Alzheimer disease ICD11: 8A20 [252]
Sotalol
 Drug Info Approved Atrial fibrillation ICD11: BC81 [27]
Upadacitinib
 Drug Info Approved Rheumatoid arthritis ICD11: FA20 [253]
Upadacitinib
 Drug Info Approved Rheumatoid arthritis ICD11: FA20 [254]
Berberine
 Drug Info Phase 4 Discovery agent ICD: N.A. [255]
Neupro
 Drug Info Phase 4 Restless legs syndrome ICD11: 7A80 [259]
Ingrezza
 Drug Info Phase 4 Dyskinesia ICD11: 8A02 [279]
      Drugs in Phase 4 Clinical Trial Click to Show/Hide the Full List of Drugs:        52 Drugs
Ajmaline
 Drug Info Phase 4 Atrial fibrillation ICD11: BC81 [55]
Sertindole
 Drug Info Phase 4 Schizophrenia ICD11: 6A20 [256]
Minaprine
 Drug Info Phase 4 Depression ICD11: 6A71 [257]
Dapoxetine
 Drug Info Phase 4 Ejaculatory dysfunction ICD11: HA03 [258]
Cinnarizine
 Drug Info Phase 4 Haemorrhagic stroke ICD11: 8B20 [13]
Alprenolol
 Drug Info Phase 4 Essential hypertension ICD11: BA00 [106]
Bevantolol
 Drug Info Phase 4 Angina pectoris ICD11: BA40 [27]
Cibenzoline
 Drug Info Phase 4 Atrial fibrillation ICD11: BC81 [260]
Mianserin
 Drug Info Phase 4 Depression ICD11: 6A71 [261]
Remoxipride
 Drug Info Phase 4 Schizophrenia ICD11: 6A20 [55]
Tropisetron
 Drug Info Phase 4 Anaesthesia ICD11: 8E22 [76]
Vonoprazan
 Drug Info Phase 4 Gastro-oesophageal reflux disease ICD11: DA22 [262]
Vonoprazan
 Drug Info Phase 4 Gastro-oesophageal reflux disease ICD11: DA22 [263]
Zotepine
 Drug Info Phase 4 Schizophrenia ICD11: 6A20 [264]
Astemizole
 Drug Info Phase 4 Allergic rhinitis ICD11: CA08 [265]
Dexfenfluramine
 Drug Info Phase 4 Obesity ICD11: 5B81 [266]
Dihydrocodeine
 Drug Info Phase 4 Anaesthesia ICD11: 8E22 [267]
Etoricoxib
 Drug Info Phase 4 Anaesthesia ICD11: 8E22 [13]
Idebenone
 Drug Info Phase 4 Mitochondrial myopathy ICD11: 8C73 [268]
Imrecoxib
 Drug Info Phase 4 Osteoarthritis ICD11: FA00 [269]
Ipecac
 Drug Info Phase 4 Pulmonary tuberculosis ICD11: 1B10 [270]
Phenacetin
 Drug Info Phase 4 Anaesthesia ICD11: 8E22 [271]
Terfenadine
 Drug Info Phase 4 Allergy ICD11: 4A80 [230]
Tertatolol
 Drug Info Phase 4 Essential hypertension ICD11: BA00 [27]
Zuclopenthixol
 Drug Info Phase 4 Schizophrenia ICD11: 6A20 [272]
Aminophenazone
 Drug Info Phase 4 Anaesthesia ICD11: 8E22 [273]
Chlorphenamine
 Drug Info Phase 4 Allergy ICD11: 4A80 [161]
Dextropropoxyphene
 Drug Info Phase 4 Lung cancer ICD11: 2C25 [274]
Encainide
 Drug Info Phase 4 Cardiac arrhythmia ICD11: BC65 [275]
Flunarizine
 Drug Info Phase 4 Schizophrenia ICD11: 6A20 [13]
Perazine
 Drug Info Phase 4 Cerebrovascular dementia ICD11: 6D81 [276]
Buflomedil
 Drug Info Phase 4 Arterial occlusive disease ICD11: BD4Z [277]
Enclomiphene
 Drug Info Phase 4 Female infertility ICD11: GA31 [278]
Indoramin
 Drug Info Phase 4 Essential hypertension ICD11: BA00 [55]
Lofexidine
 Drug Info Phase 4 Opiate dependence ICD11: 6C43 [280]
Milnacipran
 Drug Info Phase 4 Asperger syndrome ICD11: 6A02 [281]
Milnacipran
 Drug Info Phase 4 Asperger syndrome ICD11: 6A02 [282]
Milnacipran
 Drug Info Phase 4 Asperger syndrome ICD11: 6A02 [283]
Ramosetron
 Drug Info Phase 4 Irritable bowel syndrome ICD11: DD91 [284]
Amsacrine
 Drug Info Phase 4 Acute lymphoblastic leukemia ICD11: 2B33 [285]
Arotinolol
 Drug Info Phase 4 Essential tremor ICD11: 8A04 [27]
Esmirtazapine
 Drug Info Phase 4 Depression ICD11: 6A71 [286]
Guanoxan
 Drug Info Phase 4 Essential hypertension ICD11: BA00 [55]
Nicergoline
 Drug Info Phase 4 Acne vulgaris ICD11: ED80 [287]
Phenformin
 Drug Info Phase 4 Diabetes mellitus ICD11: 5A10 [11]
Practolol
 Drug Info Phase 4 Cardiac arrhythmia ICD11: BC65 [27]
Pyrantel
 Drug Info Phase 4 Hookworm disease ICD11: 1F68 [22]
Aminobutyric acid
 Drug Info Phase 4 Epilepsy ICD11: 8A60 [288]
Benzethonium
 Drug Info Phase 4 Methicillin-resistant staphylococcus infection ICD11: 1D01 [86]
Celiprolol
 Drug Info Phase 4 Essential hypertension ICD11: BA00 [27]
Indenolol
 Drug Info Phase 4 Cardiac arrhythmia ICD11: BC65 [27]
Yohimbine
 Drug Info Phase 4 Erectile dysfunction ICD11: HA01 [289]
      Drugs in Phase 3 Clinical Trial Click to Show/Hide the Full List of Drugs:        41 Drugs
Fidarestat
 Drug Info Phase 3 Diabetic complication ICD11: 5A2Y [290]
Fruquintinib
 Drug Info Phase 3 Solid tumour/cancer ICD11: 2A00-2F9Z [291]
Lisuride
 Drug Info Phase 3 Parkinsonism ICD11: 8A00 [292]
BMS-298585
 Drug Info Phase 3 Diabetes mellitus ICD11: 5A10 [293]
BMS-650032
 Drug Info Phase 3 Viral hepatitis ICD11: 1E51 [294]
Q-100648
 Drug Info Phase 3 Eclampsia ICD11: JA25 [27]
Omecamtiv mecarbil
 Drug Info Phase 3 Heart failure ICD11: BD10-BD1Z [295]
ABT-333
 Drug Info Phase 3 Viral hepatitis ICD11: 1E51 [296]
Chlorpromazine
 Drug Info Phase 3 Coronavirus Disease 2019 (COVID-19) ICD11: 1D6Y [297]
DOV-220075
 Drug Info Phase 3 Depression ICD11: 6A71 [298]
KW-5338
 Drug Info Phase 3 Gastroparesis ICD11: DA41 [299]
NE-10064
 Drug Info Phase 3 Cardiac arrhythmia ICD11: BC65 [300]
RO-111163
 Drug Info Phase 3 Hypersalivation ICD11: DA04 [301]
TRYPTAMINE
 Drug Info Phase 3 Discovery agent ICD: N.A. [302]
Bexagliflozin
 Drug Info Phase 3 Type-2 diabetes ICD11: 5A11 [303]
CEM-102
 Drug Info Phase 3 Endocarditis ICD11: 1B12 [304]
GW-1000
 Drug Info Phase 3 Cerebral vasospasm ICD11: BA85 [30]
BMS-986165
 Drug Info Phase 3 Psoriasis vulgaris ICD11: EA90 [305]
LU-AE58054
 Drug Info Phase 3 Alzheimer disease ICD11: 8A20 [306]
Hydroxychloroquine
 Drug Info Phase 3 Malaria ICD11: 1F40-1F45 [224]
LY-450139
 Drug Info Phase 3 Alzheimer disease ICD11: 8A20 [307]
R-1124
 Drug Info Phase 3 Functional nausea/vomiting ICD11: DD90 [308]
WSM-3978G
 Drug Info Phase 3 Hypertrophic cardiomyopathy ICD11: BC43 [309]
ABC294640
 Drug Info Phase 3 Advanced solid tumour ICD11: 2A00-2F9Z [310]
BRN-1907611
 Drug Info Phase 3 Inflammatory bowel disease ICD11: DD72 [311]
DW-1030
 Drug Info Phase 3 Cerebral vasospasm ICD11: BA85 [312]
Fenfluramine
 Drug Info Phase 3 Dravet syndrome ICD11: 8A61-8A6Z [313]
Imatinib
 Drug Info Phase 3 Mantle cell lymphoma ICD11: 2A85 [314]
ONO-1101
 Drug Info Phase 3 Atrial fibrillation ICD11: BC81 [27]
OPC-12759
 Drug Info Phase 3 Peptic ulcer ICD11: DA61 [315]
RSD-1235
 Drug Info Phase 3 Atrial fibrillation ICD11: BC81 [316]
BNP-1350
 Drug Info Phase 3 Ovarian cancer ICD11: 2C73 [317]
Ganaxolone
 Drug Info Phase 3 Complex partial seizure ICD11: 8A61-8A6Z [318]
MRTX849
 Drug Info Phase 3 Lung cancer ICD11: 2C25 [319]
Nitrofural
 Drug Info Phase 3 Acute tonsillitis ICD11: CA03 [320]
SEP-363856
 Drug Info Phase 3 Schizophrenia ICD11: 6A20 [321]
Sildenafil
 Drug Info Phase 3 Erectile dysfunction ICD11: HA00-HA01 [322]
Ag-221
 Drug Info Phase 3 Acute myelogenous leukaemia ICD11: 2A41 [323]
AMD-070
 Drug Info Phase 3 Whim syndrome ICD11: 4A00 [324]
Elagolix
 Drug Info Phase 3 Uterine leiomyoma ICD11: 2E86 [325]
FT-0710230
 Drug Info Phase 3 Opiate dependence ICD11: 6C43 [326]
      Drugs in Phase 2 Clinical Trial Click to Show/Hide the Full List of Drugs:        42 Drugs
Emixustat
 Drug Info Phase 2/3 Age-related macular degeneration ICD11: 9B75 [327]
Verapamil
 Drug Info Phase 2/3 Hypertension ICD11: BA00-BA04 [328]
CS-505
 Drug Info Phase 2/3 Arteriosclerosis obliterans ICD11: BD40 [329]
Fexinidazole
 Drug Info Phase 2/3 Trypanosomiasis ICD11: 1D51-1F53 [330], [331]
Fexinidazole
 Drug Info Phase 2/3 Trypanosomiasis ICD11: 1D51-1F53 [331]
HOE-239
 Drug Info Phase 2/3 Trypanosomiasis ICD11: 1F51 [331]
MJ-13105
 Drug Info Phase 2/3 Atrial fibrillation ICD11: BC81 [27]
PF-00734200
 Drug Info Phase 2 Type-2 diabetes ICD11: 5A11 [332]
Leniolisib
 Drug Info Phase 2 Sjogren syndrome ICD11: 4A43 [333]
AZD8931
 Drug Info Phase 2 Breast cancer ICD11: 2C60-2C6Y [334]
BLZ-945
 Drug Info Phase 2 Amyotrophic lateral sclerosis ICD11: 8B60 [335]
BMS-690514
 Drug Info Phase 2 Chronic pain ICD11: MG30 [336]
BS-3952
 Drug Info Phase 2 Essential hypertension ICD11: BA00 [337]
CCRIS-9277
 Drug Info Phase 2 Posttraumatic stress disorder ICD11: 6B40 [338]
Roxatidine
 Drug Info Phase 2 Gastro-oesophageal reflux disease ICD11: DA22 [339]
SQ-109
 Drug Info Phase 2 Pulmonary tuberculosis ICD11: 1B10 [340]
PD-143188
 Drug Info Phase 2 Psychotic disorder ICD11: 6A20-6A25 [341]
PT2385
 Drug Info Phase 2 Von hippel-lindau disease ICD11: 5A75 [342]
VATALANIB
 Drug Info Phase 2 Solid tumour/cancer ICD11: 2A00-2F9Z [343]
VATALANIB
 Drug Info Phase 2 Solid tumour/cancer ICD11: 2A00-2F9Z [344]
BCP-13498
 Drug Info Phase 2 Anaesthesia ICD11: 8E22 [345]
CP-101,606
 Drug Info Phase 2 Parkinsonism ICD11: 8A00 [346]
SSR-97193
 Drug Info Phase 2 Malaria ICD11: 1F40 [347]
HP-184
 Drug Info Phase 2 Multiple sclerosis ICD11: 8A40 [348]
Org-33062
 Drug Info Phase 2 Cocaine addiction ICD11: 6C45 [349]
Saracatinib
 Drug Info Phase 2 Osteosarcoma ICD11: 2B51 [350]
AV-650
 Drug Info Phase 2 Cerebral vasospasm ICD11: BA85 [351]
CP-122721
 Drug Info Phase 2 Depression ICD11: 6A71 [352]
Vincamine
 Drug Info Phase 2 Cerebrovascular dementia ICD11: 6D81 [353]
Ym-758
 Drug Info Phase 2 Angina pectoris ICD11: BA40 [354]
JI-101
 Drug Info Phase 2 Solid tumour/cancer ICD11: 2A00-2F9Z [355]
LY-2603618
 Drug Info Phase 2 Pancreatic cancer ICD11: 2C10 [356]
WR-6026
 Drug Info Phase 2 Protozoan infection ICD11: 1F5Z [357]
AZD-2327
 Drug Info Phase 2 Anxiety disorder ICD11: 6B00-6B0Z [358]
CIMICOXIB
 Drug Info Phase 2 Pain ICD11: MG30-MG3Z [359]
Nuplazid
 Drug Info Phase 2 Alzheimer disease ICD11: 8A20 [360]
PTC299
 Drug Info Phase 2 Solid tumour/cancer ICD11: 2A00-2F9Z [361]
TAK-906
 Drug Info Phase 2 Gastroparesis ICD11: DA41 [362]
KD025
 Drug Info Phase 2 Psoriasis vulgaris ICD11: EA90 [363]
KW-4354
 Drug Info Phase 2 Muscular dystrophy ICD11: 8C70 [364]
P-459
 Drug Info Phase 2 Staphylococcus infection ICD11: 1B73 [55]
Prajmaline
 Drug Info Phase 2 Atherosclerosis ICD11: BA80 [365]
      Drugs in Phase 1 Clinical Trial Click to Show/Hide the Full List of Drugs:        16 Drugs
G-33040
 Drug Info Phase 1/2 Anxiety disorder ICD11: 6B00 [55]
TRV-130
 Drug Info Phase 1/2 Hypothyroidism ICD11: 5A00 [366]
GTPL7557
 Drug Info Phase 1/2 Schizophrenia ICD11: 6A20 [367]
AST-1306
 Drug Info Phase 1 Solid tumour/cancer ICD11: 2A00-2F9Z [368]
BE-14348A
 Drug Info Phase 1 Viral hepatitis ICD11: 1E51 [369]
H3B-6545
 Drug Info Phase 1 Breast cancer ICD11: 2C60 [370]
M-813
 Drug Info Phase 1 Schizophrenia ICD11: 6A20 [371]
Alvespimycin hydrochloride
 Drug Info Phase 1 Ovarian cancer ICD11: 2C73 [372]
Benzoylphenylurea
 Drug Info Phase 1 Solid tumour/cancer ICD11: 2A00-2F9Z [373], [374]
MP-513
 Drug Info Phase 1 Diabetes mellitus ICD11: 5A10 [375], [376]
AC-1802
 Drug Info Phase 1 Cardiac arrhythmia ICD11: BC65 [377]
CCRIS-4201
 Drug Info Phase 1 Essential hypertension ICD11: BA00 [27]
GTPL-1666
 Drug Info Phase 1 Cerebral vasospasm ICD11: BA85 [378]
NSC-172130
 Drug Info Phase 1 Depression ICD11: 6A71 [379]
OSI-930
 Drug Info Phase 1 Solid tumour/cancer ICD11: 2A00-2F9Z [380]
ITX-5061
 Drug Info Phase 1 Human immunodeficiency virus infection ICD11: 1C60 [381]
      Discontinued/withdrawn Drugs Click to Show/Hide the Full List of Drugs:        24 Drugs
Cilomilast
 Drug Info Discontinued in Phase 3 Emphysema ICD11: CA21 [382]
Motesanib
 Drug Info Discontinued in Phase 3 Lung cancer ICD11: 2C25 [383]
Almokalant
 Drug Info Discontinued in Phase 3 Cardiac arrhythmias ICD11: BC9Z [384]
Avitriptan
 Drug Info Discontinued in Phase 3 Migraine ICD11: 8A80 [385]
AZD0328
 Drug Info Discontinued in Phase 2 Alzheimer disease ICD11: 8A20 [386]
TAK-802
 Drug Info Discontinued in Phase 2 Urinary dysfunction ICD11: GC2Z [387]
YM-992
 Drug Info Discontinued in Phase 2 Depression ICD11: 6A70-6A7Z [388]
BMS-181168
 Drug Info Discontinued in Phase 2 Cognitive impairment ICD11: 6D71 [389]
Ispronicline
 Drug Info Discontinued in Phase 2 Schizophrenia ICD11: 6A20 [390]
ABT-107
 Drug Info Discontinued in Phase 1 Attention deficit hyperactivity disorder ICD11: 6A05 [391]
E2101
 Drug Info Discontinued in Phase 1 Dyskinesia ICD11: 8A02 [392]
YM-17E
 Drug Info Discontinued in Phase 1 Hypertriglyceridaemia ICD11: 5C80 [393]
CJ-11974
 Drug Info Discontinued Irritable bowel syndrome ICD11: DD91 [394]
CAM-2028
 Drug Info Discontinued Acute nasopharyngitis ICD11: CA00 [395]
ML-3000
 Drug Info Discontinued Osteoarthritis ICD11: FA00 [13]
BMY-42569
 Drug Info Discontinued Depression ICD11: 6A71 [396]
R-58735
 Drug Info Discontinued Cerebral ischaemia ICD11: 8B1Z [397]
CGP-11305A
 Drug Info Discontinued Anxiety disorder ICD11: 6B00 [398]
INN-00835
 Drug Info Discontinued Depression ICD11: 6A71 [399]
Octopamine
 Drug Info Discontinued Thrombosis ICD11: DB61 [400]
RD-4593
 Drug Info Discontinued Depression ICD11: 6A71 [401]
TS-702
 Drug Info Discontinued Angina pectoris ICD11: BA40 [27]
TV-1203
 Drug Info Discontinued Parkinsonism ICD11: 8A00 [402]
YMB-1002
 Drug Info Discontinued Breast cancer ICD11: 2C60 [403]
      Preclinical/investigative Agents Click to Show/Hide the Full List of Drugs:        23 Drugs
EPX-100
 Drug Info Preclinical Dravet syndrome ICD11: 8A61 [404]
Q-100155
 Drug Info Preclinical Rheumatoid arthritis ICD11: FA20 [405]
Befunolol
 Drug Info Investigative Glaucoma ICD11: 9C61 [27]
Ethylmorphine
 Drug Info Investigative Discovery agent ICD: N.A. [406]
Bufuralol
 Drug Info Investigative Cardiac arrhythmia ICD11: BC65 [407]
Butyrfentanyl
 Drug Info Investigative Anaesthesia ICD11: 8E22 [408]
Bromazepam
 Drug Info Investigative Anxiety disorder ICD11: 6B00 [409]
Methoxyamphetamine beta
 Drug Info Investigative Discovery agent ICD: N.A. [410]
Antipyrine
 Drug Info Investigative Discovery agent ICD: N.A. [411]
Chloroxylenol
 Drug Info Investigative Pseudomonas infection ICD11: 1G40 [55]
Desmethylastemizole
 Drug Info Investigative Discovery agent ICD: N.A. [265]
Linalool
 Drug Info Investigative Colon cancer ICD11: 2B90 [412], [413], [414]
Methoxyphenamine
 Drug Info Investigative Chronic obstructive pulmonary disease ICD11: CA22 [415]
Bupranolol
 Drug Info Investigative Ventricular tachyarrhythmia ICD11: BC71 [55]
Mequitazine
 Drug Info Investigative Allergic rhinitis ICD11: CA08 [416]
Methoxybufotenin
 Drug Info Investigative Discovery agent ICD: N.A. [417]
Sparteine
 Drug Info Investigative Cardiac arrhythmia ICD11: BC65 [131]
Bopindolol
 Drug Info Investigative Discovery agent ICD: N.A. [27]
Etilamfetamine
 Drug Info Investigative Pulmonary hypertension ICD11: BB01 [157]
Lorpiprazole
 Drug Info Investigative Anxiety disorder ICD11: 6B00 [418]
Repinotan
 Drug Info Investigative Discovery agent ICD: N.A. [419]
Cloranolol
 Drug Info Investigative Discovery agent ICD: N.A. [27]
Mepindolol
 Drug Info Investigative Glaucoma ICD11: 9C61 [27]
Full List of Metabolic Reactions (MR) Catalyzed by This DME
MR ID Reactant Product MR Type Source Drug REF
MR011470 ABT-107 ABT-107 Metabolite M2 Unclear - Unclear ABT-107 [391]
MR006154 AC-1802 N-[3-(N,NDiethylamino)propyl]-N-phenyl-2-aminoindan-5-ol Oxidation - Aromatic hydroxylation AC-1802 [420]
MR006155 AC-1802 p-Hydroxyphenylaprindine Oxidation - Aromatic hydroxylation AC-1802 [420]
MR006156 AC-1802 Desethylaprindine Oxidation - N-dealkylation AC-1802 [420]
MR000050 Acetaminophen NAPQI Oxidation - Oxidation Acetaminophen [421], [422]
MR008995 Almogran N-desmethylalmotriptan Oxidation - N-demethylation Almogran [423]
MR008988 Almogran 2-OH-almotriptan Oxidation - Aliphatic hydroxylation Almogran [24]
MR008998 Almogran 1-[({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methane)sulfonyl]pyrrolidin-2-ol Oxidation - Oxidation Almogran [423]
MR009416 Almokalant Almokalant Metabolite M13 Oxidation - Sulfoxidation Almokalant [384]
MR009417 Almokalant Almokalant Metabolite M16 Unclear - Unclear Almokalant [384]
MR009419 Almokalant Almokalant Metabolite M3 Unclear - Unclear Almokalant [384]
MR000155 Almotriptan malate LAS 31612 Oxidation - N-Demethylation Almotriptan malate [26], [25]
MR000153 Almotriptan malate Almotriptan malate metabolite M3 Oxidation - Pyrrolidine Oxidation Almotriptan malate [25]
MR000158 Alogliptin Alogliptin M2 Oxidation - Deamination Alogliptin [186]
MR009781 17-DMAG M2 17-DMAG M6 Oxidation - Hydroxylation Alvespimycin hydrochloride [372]
MR000170 Aminophenazone N-Desmethylaminopyrine Oxidation - N-Dealkylation Aminophenazone [13]
MR000169 Aminophenazone 4-(Dimethylamino)-5-methyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one Oxidation - N-Dealkylation Aminophenazone [424]
MR009861 (E)-10-hydroxyamitriptyline (E)-10-hydroxynortriptyline Unclear - Unclear Amitriptyline hydrochloride [425], [426]
MR009860 Amitriptyline hydrochloride (E)-10-hydroxyamitriptyline Unclear - Unclear Amitriptyline hydrochloride [425], [426]
MR000205 Amoxapine 7-hydroxyamoxapine Oxidation - Hydroxylation Amoxapine [427], [428]
MR000220 Amphetamine 4-hydroxyamphetamine Oxidation - Hydroxylation Amphetamine [424]
MR013473 Arformoterol O-Desmethylarformoterol Oxidation - O-dealkylation Arformoterol [429], [430], [431]
MR000290 Aripiprazole Dehydro-aripiprazole Oxidation - Dehydrogenation Aripiprazole lauroxil [432], [433]
MR005993 Arotinolol AC-623 Unclear - Unclear Arotinolol [434]
MR009797 AST-1306 Allitinib M10 Unclear - Unclear AST-1306 [368]
MR000331 Astemizole 6-hydroxyastemizole Oxidation - Hydroxylation Astemizole [265]
MR002933 Atenolol Atenolol metabolite M1 Oxidation - Hydroxylation Atenolol [435], [436]
MR009872 4-hydroxyatomoxetine 4-hydroxyatomnoxetine-O-glucuronide Conjugation - Glucuronidation Atomoxetine hydrochloride [437]
MR009871 Atomoxetine hydrochloride 4-hydroxyatomoxetine Unclear - Unclear Atomoxetine hydrochloride [437]
MR007277 AV-650 AV-650 M1 Unclear - Unclear AV-650 [351]
MR009432 Avitriptan OD048 Oxidation - O-desmethylation Avitriptan [385]
MR012382 AZD-2327 N-deethylated AZD-2327 Oxidation - N-deethylation AZD-2327 [358]
MR009369 AZD0328 AZD0328 Metabolite M6 Oxidation - N-oxidation AZD0328 [386]
MR007296 Paracetamol N-acetil-p-benzoquinone imine Unclear - Unclear BCP-13498 [345]
MR003839 BE-14348A Eriodictyol Oxidation - Hydrolyzationn BE-14348A [369]
MR008758 Benzocaine Benzocaine hydroxylamine Oxidation - N-hydroxylation Benzocaine [159]
MR010376 Benzoylphenylurea MmBPU Oxidation - Desmethylation Benzoylphenylurea [373], [374]
MR013779 Berberine Demethyleneberberine Oxidation - Demethylenation Berberine [438], [255]
MR013789 Berberine Thalfendine Oxidation - Demethylation Berberine [438], [255], [439]
MR013787 Berberine Berberrubine Oxidation - Demethylation Berberine [438], [255], [439]
MR013780 Demethyleneberberine 2,3,10-trihydroxyberberine Oxidation - Demethylation Berberine [438], [255]
MR008943 Betrixaban N-desmethylbetrixaban Oxidation - N-demethylation Betrixaban [87]
MR011594 Bexagliflozin EGT0001301 Oxidation - Oxidation Bexagliflozin [303]
MR000372 Binimetinib 1,4-Diiminoquinone intermediate Oxidation - Two-Electron Oxidation Binimetinib [160]
MR000374 Bisoprolol Bisoprolol metabolite M4 Oxidation - O-Dealkylation Bisoprolol [440]
MR000378 BMS-298585 BMS-298585 metabolite M16 Unclear - Unclear BMS-298585 [293], [441]
MR000376 BMS-298585 BMS-298585 metabolite M1 Oxidation - O-Dealkylation BMS-298585 [293], [441]
MR000379 BMS-298585 BMS-298585 metabolite M15 Unclear - Unclear BMS-298585 [293], [441]
MR012504 BMS-690514 BMS-690514 M2 Unclear - Unclear BMS-690514 [442]
MR005473 BMS-986165 Deucravacitinib M11 metabolite Oxidation - Oxidationn BMS-986165 [443]
MR000396 BNP-1350 . Unclear - Unclear BNP-1350 [444]
MR000411 Bortezomib Bortezomib metabolite M23 Unclear - Unclear Bortezomib [13]
MR000412 Bortezomib Bortezomib metabolite M24 Unclear - Unclear Bortezomib [13]
MR000409 Bortezomib Bortezomib metabolite M2 Oxidation - Oxidation; Deboronation Bortezomib [13]
MR000408 Bortezomib Bortezomib metabolite M1 Oxidation - Oxidative Deboronation Bortezomib [13]
MR000421 BPI-2009 BPI-2009 metabolite M11 Oxidation - Hydroxylation BPI-2009 [445]
MR000422 BPI-2009 BPI-2009 metabolite M6 Oxidation - Oxidation BPI-2009 [445]
MR000423 BPI-2009 BPI-2009 metabolite M7 Oxidation - Oxidation BPI-2009 [445]
MR000424 BPI-2009 BPI-2009 metabolite M8 Oxidation - Oxidation BPI-2009 [445]
MR000436 Brexpiprazole Brexpiprazole S-oxide Unclear - Unclear Brexpiprazole [63], [446]
MR000455 BRN-1907611 8-hydroxycamphor Oxidation - Hydroxylation BRN-1907611 [412], [311]
MR007576 Bromazepam Unclear Unclear - Unclear Bromazepam [409]
MR000458 Bromfenac indolinone Bromfenac metabolite M3 Unclear - Unclear Bromfenac [447], [448]
MR007381 BS-3952 S-(+)-4-hydroxydebrisoquine Unclear - Unclear BS-3952 [449]
MR007577 Bufuralol 1'-Hydroxybufuralol Oxidation - Hydrolyzationn Bufuralol [450]
MR000481 Bupivacaine hydrochloride N-desbutylbupivacaine Unclear - Unclear Bupivacaine hydrochloride [451]
MR007582 Bupranolol Unclear Unclear - Unclear Bupranolol [452]
MR000524 Buspirone Buspirone N-oxide Oxidation - N-Oxidation Buspirone [453]
MR007584 Butyrfentanyl Omega-hydroxy-butyrylfentany Oxidation - Hydrolyzationn Butyrfentanyl [454], [408]
MR005916 CAM-2028 Norbenzydamine Unclear - Unclear CAM-2028 [455]
MR002818 Capsaicin Capsaicin metabolite M1 Oxidation - Dehydrogenation Capsaicin [31]
MR002819 Capsaicin Capsaicin metabolite M2 Oxidation - Omega-Hydroxylation Capsaicin [31]
MR002820 Capsaicin Capsaicin metabolite M3 Oxidation - Omega-1-Hydroxylation Capsaicin [31]
MR002821 Capsaicin Capsaicin metabolite M4 Oxidation - Dehydrogenation Capsaicin [31]
MR002822 Capsaicin Capsaicin metabolite M5M7 Oxidation - Hydroxylation Capsaicin [31]
MR002823 Capsaicin Capsaicin metabolite M6 Oxidation - O-Dehydrogenation Capsaicin [31]
MR002824 Capsaicin Capsaicin metabolite M8 Oxidation - N-Dehydrogenation; Oxygenation Capsaicin [31]
MR002825 Capsaicin Capsaicin metabolite M9 Oxidation - N-Dehydrogenation Capsaicin [31]
MR003126 Cariprazine hydrochloride Desmethyl cariprazine Oxidation - Demethylation Cariprazine hydrochloride [190]
MR003127 Cariprazine hydrochloride Didesmethyl cariprazine Oxidation - Demethylation Cariprazine hydrochloride [190]
MR003125 Desmethyl cariprazine Didesmethyl cariprazine Oxidation - Demethylation Cariprazine hydrochloride [190]
MR002592 Carteolol hydrochloride 8-hydroxycarteolol Oxidation - 8-Hydroxylation Carteolol hydrochloride [191]
MR000570 Carvedilol 4'-hydroxyphenylcarvedilol Oxidation - 4'-Hydroxylation Carvedilol [456]
MR000572 Carvedilol O-Desmethylcarvedilol Oxidation - O-Demethylation Carvedilol [456]
MR000573 Carvedilol 1-hydroxyphenylcarvedilol Oxidation - 1-Hydroxylation Carvedilol [456]
MR000571 Carvedilol 5'-hydroxyphenylcarvedilol Oxidation - 5'-Hydroxylation Carvedilol [456]
MR007393 CBL-0102 Unclear Oxidation - N-desethylation CBL-0102 [457]
MR007405 CCRIS-9277 HHMA Oxidation - O-demethylation CCRIS-9277 [338]
MR007408 HHMA HMMA Oxidation - O-demethylation CCRIS-9277 [338]
MR000587 Celecoxib Hydroxycelecoxib Oxidation - Hydroxylation Celecoxib [458]
MR000609 Cevimeline hydrochloride Cevimeline trans-sulfoxide Oxidation - Sulfoxidation Cevimeline hydrochloride [459]
MR000611 Cevimeline hydrochloride Cevimeline cis-sulfoxidation Oxidation - Sulfoxidation Cevimeline hydrochloride [459]
MR013662 CGP-11305A O-desmethyl-brofaromine Unclear - Unclear CGP-11305A [460]
MR000628 Chloroquine (R)-chloroquine, N-desethyl Oxidation - N-Dealkylation Chloroquine [461], [224], [462]
MR006255 Chloroxylenol Unclear Unclear - Unclear Chloroxylenol [55]
MR000633 Chlorphenamine Monodesmethylchlorpheniramine Unclear - Unclear Chlorphenamine [463]
MR000639 Chlorpheniramine Monodesmethylchlorpheniramine Unclear - Unclear Chlorpheniramine [463]
MR011380 Chlorpromazine Hydroxychlorpromazine Oxidation - 7-hydroxylation Chlorpromazine [297]
MR000643 Chlorpromazine hydrochloride Hydroxychlorpromazine Oxidation - 7-Hydroxylation Chlorpromazine hydrochloride [464], [465]
MR000649 Chlorpropamide 3-hydroxychlorpropamide Oxidation - 2-Hydroxylation Chlorpropamide [13]
MR003606 Cibenzoline p-hydroxycibenzoline Oxidation - Hydrolyzationn Cibenzoline [260]
MR003205 Desisobutyrylciclesonide Ciclesonide metabolite M3 Unclear - Unclear Ciclesonide [466]
MR012491 Cimicoxib Demethyl-cimicoxib Unclear - Unclear Cimicoxib [359]
MR013304 Cinnarizine Cinnarizine metabolite M2 Oxidation - Hydrolyzationn Cinnarizine [13]
MR006517 Citalopram hydrobromide Demethylcitalopram Oxidation - N-demethylation Citalopram hydrobromide [467], [468]
MR006523 Citalopram hydrobromide Citalopram-N-oxide Oxidation - Oxidationn Citalopram hydrobromide [468]
MR006518 Demethylcitalopram Didemethylcitalopram Oxidation - N-demethylation Citalopram hydrobromide [468]
MR005924 CJ-11974 M16 CL12764 Unclear - Unclear CJ-11974 [469]
MR005935 CJ-11974 M17 CJ-12458 Unclear - Unclear CJ-11974 [469]
MR008660 (E)-4-OH-CLOM (E)-4-OH-DE-CLOM Unclear - Unclear Clomiphene citrate [51]
MR008658 (E)-DE-CLOM (E)-4-OH-DE-CLOM Unclear - Unclear Clomiphene citrate [51]
MR008657 (E)-DE-CLOM (E)-DDE-CLOM Unclear - Unclear Clomiphene citrate [51]
MR008656 Clomiphene citrate (E)-DE-CLOM Unclear - Unclear Clomiphene citrate [51]
MR008664 Clomiphene citrate (Z)-DE-CLOM Unclear - Unclear Clomiphene citrate [51]
MR008659 Clomiphene citrate (E)-4-OH-CLOM Unclear - Unclear Clomiphene citrate [51]
MR008662 Clomiphene citrate (E)-DDE-CLOM Unclear - Unclear Clomiphene citrate [51]
MR009002 2-hydroxyclomipramine 2-hydroxydesmethyl clomipramine Oxidation - Demethylation Clomipramine [40]
MR009001 Clomipramine 2-hydroxyclomipramine Oxidation - 2-hydroxylation Clomipramine [40]
MR009005 Clomipramine 8-hydroxyclomipramine Oxidation - 8-hydroxylation Clomipramine [40]
MR009012 Clomipramine 8-OH-clomipramine Oxidation - Aromatic hydroxylation Clomipramine [40]
MR009013 Clomipramine 10-OH-clomipramine Oxidation - Aliphatic hydroxylation Clomipramine [40]
MR006572 2-hydroxyclomipramine 2-hydroxydesmethyl clomipramine Oxidation - Demethylation Clomipramine hydrochloride [470]
MR006574 Clomipramine hydrochloride 8-hydroxyclomipramine Oxidation - 8-hydroxylation Clomipramine hydrochloride [471]
MR006578 Clomipramine hydrochloride Clomipramine N-oxide Oxidation - Oxidationn Clomipramine hydrochloride [471]
MR006579 Clomipramine hydrochloride 8-OH-clomipramine Oxidation - Aromatic hydroxylation Clomipramine hydrochloride [470]
MR006580 Clomipramine hydrochloride 10-OH-clomipramine Oxidation - Aliphatic hydroxylation Clomipramine hydrochloride [471]
MR006568 Desmethylclomipramine 2-hydroxydesmethyl clomipramine Oxidation - Demethylation Clomipramine hydrochloride [470]
MR006587 Clonidine 4-Hydroxyclonidine Oxidation - 4-hydroxylation Clonidine [124]
MR002835 Clozapine N-desmethylclozapine Oxidation - N-Demethylation Clozapine [13]
MR000685 Cobicistat Cobicistat metabolite M3 Unclear - Unclear Cobicistat [472]
MR000686 Cobicistat Cobicistat metabolite M9 Unclear - Unclear Cobicistat [472]
MR000687 Cobicistat Cobicistat metabolite M2 Unclear - Unclear Cobicistat [472]
MR000689 Cobicistat Cobicistat metabolite M1 Unclear - Unclear Cobicistat [472]
MR000694 Cobicistat Cobicistat metabolite M18 Unclear - Unclear Cobicistat [472]
MR000677 Cobicistat metabolite M2 Cobicistat metabolite M4 Unclear - Unclear Cobicistat [472]
MR004095 Norcodeine Normorphine Oxidation - O-demethylation Codeine [473]
MR011733 CP-101,606 CP-101,606 Metabolite M13 Unclear - Unclear CP-101,606 [346]
MR007417 CP-122721 CP-125611 Oxidation - O-demethylation CP-122721 [352], [474]
MR006514 CS-505 R-125528 Oxidation - Oxidationn CS-505 [329]
MR009669 Curcumin O-demethyl curcumin Oxidation - O-dealkylation Curcumin [13]
MR000716 Dacomitinib PF-05199265 Oxidation - O-Demethylation Dacomitinib [227], [475]
MR002839 Dapagliflozin Dapagliflozin BMS-511926 Oxidation - O-Deethylation Dapagliflozin [476]
MR002840 Dapagliflozin Dapagliflozin BMS-639432 Oxidation - Hydroxylation Dapagliflozin [476]
MR007081 Dapoxetine Dapoxetine-n-oxide Oxidation - Oxidationn Dapoxetine [477]
MR007076 Dapoxetine Metabolite M1 Desmethyldapoxetine Oxidation - Demethylation Dapoxetine [258], [478], [479]
MR000736 Darifenacin hydrobromide UK-148,993 Oxidation - Hydroxylation Darifenacin hydrobromide [92]
MR000737 Darifenacin hydrobromide Phenyl hydroxylate Oxidation - Hydroxylation Darifenacin hydrobromide [92]
MR000740 Darifenacin hydrobromide UK-222,247 Unclear - Unclear Darifenacin hydrobromide [92]
MR000758 Deferasirox Deferasirox metabolite M4 Conjugation - O-Glucuronidation Deferasirox [480]
MR003252 Delamanid (4RS,5S)-DM-6720 Unclear - Unclear Delamanid [481]
MR002595 Desipramine 2-hydroxydesipramine Oxidation - 2-Hydroxylation Desipramine [482]
MR000770 Desloratadine 5-hydroxydesloratadine Oxidation - Hydroxylation Desloratadine [164]
MR000771 Desloratadine 6-hydroxydesloratadine Oxidation - Hydroxylation Desloratadine [164]
MR006260 Desmethylastemizole 6-Hydroxydesmethylastemizole Oxidation - 6-Hydrolyzationn Desmethylastemizole [265]
MR000781 Cis (2,3)-Dihydro Tetrabenazine-d6 D3-9-O-Desmethyl-beta-Htbz Oxidation - Demethylation Deutetrabenazine [483]
MR000782 Cis (2,3)-Dihydro Tetrabenazine-d6 D3-10-O-Desmethyl-beta-Htbz Oxidation - Demethylation Deutetrabenazine [483]
MR000783 Cis (2,3)-Dihydro Tetrabenazine-d6 Deutetrabenazine metabolite M1 Unclear - Unclear Deutetrabenazine [483]
MR000777 D6alpha-dihydrotetrabenazine D3-9-O-Desmethyl-Alpha-Htbz Oxidation - Demethylation Deutetrabenazine [483]
MR000778 D6alpha-dihydrotetrabenazine D3-10-O-Desmethyl-Alpha-Htbz Oxidation - Demethylation Deutetrabenazine [483]
MR005710 Dexchlorpheniramine maleate Didesmethyl-chlorpheniramine Oxidation - Demethylation Dexchlorpheniramine maleate [161]
MR005711 Dexchlorpheniramine maleate N-desmethyl-chlorpheniramine Oxidation - Demethylation Dexchlorpheniramine maleate [161]
MR007102 Dexfenfluramine Nordexfenfluramine Oxidation - N-dealkylation Dexfenfluramine [266]
MR000810 Dextroamphetamine 4-hydroxyamphetamine Oxidation - Hydroxylation Dextroamphetamine [484]
MR000816 (+)-3-Methoxymorphinan 3-hydroxymorphinan Oxidation - O-Demethylation Dextromethorphan hydrobromide [485]
MR000818 Dextromethorphan hydrobromide (+)-3-Methoxymorphinan Oxidation - N-Demethylation Dextromethorphan hydrobromide [485], [486]
MR000817 Dextromethorphan hydrobromide Dextrorphan Oxidation - O-Demethylation Dextromethorphan hydrobromide [485], [486]
MR000811 Dextrorphan 3-hydroxymorphinan Oxidation - N-Demethylation Dextromethorphan hydrobromide [13], [486]
MR007109 Dextropropoxyphene Nordextropropoxyphene Oxidation - N-demethyiation Dextropropoxyphene [487], [488]
MR007115 Dihydrocodeine Dihydromorphine Oxidation - O-demethylation Dihydrocodeine [489], [490]
MR000866 Deacetyl diltiazem Deacetyl O-desmethyl diltiazem Oxidation - O-Demethylation Diltiazem hydrochloride [491], [492]
MR000865 Deacetyl N-monodesmethyl diltiazem Deacetyl N,O-didesmethyl diltiazem Oxidation - O-Demethylation Diltiazem hydrochloride [492]
MR000870 Diltiazem hydrochloride O-desmethyl diltiazem Oxidation - O-Demethylation Diltiazem hydrochloride [492]
MR000864 N-monodesmethyl diltilazem N,O-didesmethyl diltiazem Oxidation - O-Demethylation Diltiazem hydrochloride [491], [492]
MR011193 Diphenhydramine N-Desmethyldiphenhydramine Unclear - Unclear Dimenhydrinate [13]
MR000876 Diphenhydramine N-desmethyldiphenhydramine Oxidation - N-Demethylation Diphenhydramine [126], [13], [493], [494]
MR000872 N-desmethyldiphenhydramine N,N-didesmethyldiphenhydramine Oxidation - N-Demethylation Diphenhydramine [126], [13], [493]
MR009912 DOV-220075 DOV-220075 Metabolite M12 Unclear - Unclear DOV-220075 [298]
MR006661 Doxepin hydrochloride N-desmethyldoxepin Oxidation - N-demethylation Doxepin hydrochloride [40]
MR006668 Doxepin hydrochloride (E)-2-hydroxydoxepin Oxidation - Hydrolyzationn Doxepin hydrochloride [495]
MR006662 N-desmethyldoxepin Hydroxydesmethyl doxepin Oxidation - Hydrolyzationn Doxepin hydrochloride [40]
MR006715 Duloxetine hydrochloride 5-hydroxy duloxetine Oxidation - Hydrolyzationn Duloxetine hydrochloride [44]
MR006009 DW-1030 DW-1030 Metabolite M4 Unclear - Unclear DW-1030 [312]
MR006010 DW-1030 Metabolite M4 DW-1030 Metabolite M2 Unclear - Unclear DW-1030 [312]
MR007446 E-7070 Unclear Unclear - Unclear E-7070 [496]
MR012208 E2101 E2101 M2 Unclear - Unclear E2101 [392]
MR012209 E2101 M2 E2101 M3 Unclear - Unclear E2101 [392]
MR006849 Eletriptan hydrobromide N-Desmethyl eletriptan Oxidation - N-demethylation Eletriptan hydrobromide [195]
MR006851 Eliglustat tartrate Genz-256416 Oxidation - Oxidationn Eliglustat tartrate [497]
MR006855 Eliglustat tartrate Genz-311752 Oxidation - Oxidationn Eliglustat tartrate [497]
MR006852 Genz-256416 Genz-258162 Oxidation - Oxidationn Eliglustat tartrate [497]
MR010500 ACU-5116 ACU-5124 Oxidation - Hydroxylation Emixustat [327], [498]
MR010501 ACU-5116 ACU-5149 Oxidation - Hydroxylation Emixustat [327], [498]
MR010502 ACU-5116 ACU-5144 Oxidation - Hydroxylation Emixustat [327], [498]
MR010503 ACU-5116 ACU-5145 Oxidation - Hydroxylation Emixustat [327], [498]
MR010506 Emixustat ACU-4861 Oxidation - Hydroxylation Emixustat [327], [498]
MR010507 Emixustat ACU-4949 Oxidation - Hydroxylation Emixustat [327], [498]
MR010508 Emixustat ACU-4982 Oxidation - Hydroxylation Emixustat [327], [498]
MR010509 Emixustat Emixustat Metabolite M20 Oxidation - Hydroxylation Emixustat [327], [498]
MR007125 Encainide O-desmethylencainide Oxidation - Demethylation Encainide [499], [66]
MR007130 Enclomiphene 4-hydroxy clomiphenet Oxidation - Hydroxlyation Enclomiphene [278]
MR006869 Encorafenib Encorafenib dealkylation Oxidation - N-dealkylation Encorafenib [229]
MR000908 Epinastine 9,13b-dehydroepinastine Unclear - Unclear Epinastine [500]
MR006964 EPX-100 EPX-100 M1 Oxidation - Oxidationn EPX-100 [404]
MR000917 Erdafitinib Erdafitinib metabolite M11 Unclear - Unclear Erdafitinib [501]
MR000918 Erdafitinib Erdafitinib metabolite M5 Oxidation - O-Demethylation Erdafitinib [501]
MR000919 Erdafitinib Erdafitinib metabolite M6 Oxidation - O-Demethylation Erdafitinib [501]
MR000921 Erdafitinib Erdafitinib metabolite M28 Unclear - Unclear Erdafitinib [501]
MR000942 Escitalopram S-desmethylcitalopram Oxidation - N-Demethylation Escitalopram [467], [502]
MR000941 S-desmethylcitalopram S-didesmethylcitalopram Oxidation - N-Demethylation Escitalopram [467]
MR007140 Esmirtazapine Unclear Unclear - Unclear Esmirtazapine [286]
MR002696 Estrone 2-hydroxyestrone Oxidation - Hydroxylation Estrone [503]
MR012875 Morphine Morphine-6-glucuronide Unclear - Unclear Ethylmorphine [504]
MR007168 6-Hydroxymethyletoricoxib 6-Hydroxymethyletoricoxib-1'-N'-oxide Oxidation - 1-N-oxidation Etoricoxib [13]
MR007163 Etoricoxib Etoricoxib 1'-N'-oxide Oxidation - 1-N-oxidation Etoricoxib [13]
MR007165 Etoricoxib 6-Hydroxymethyletoricoxib Other reaction - 6-methylhydroxylation Etoricoxib [13]
MR007164 Etoricoxib 1'-N'-oxide 6-Hydroxymethyletoricoxib-1'-N'-oxide Other reaction - 6-methylhydroxylation Etoricoxib [505]
MR012196 Fenfluramine Norfenfluramine Unclear - Unclear Fenfluramine [506]
MR001028 Fesoterodine Fesoterodine carboxy-N-desisopropyl metabolite Unclear - Unclear Fesoterodine [507], [508]
MR001029 Fesoterodine Fesoterodine N-desisopropyl metabolite Unclear - Unclear Fesoterodine [507], [508]
MR001026 Fesoterodine 5-hydroxymethyl tolterodine Fesoterodine carboxy metabolite Unclear - Unclear Fesoterodine [507], [508]
MR005476 Fexinidazole Fexinidazole sulfoxide metabolite (M1) Oxidation - Oxidationn Fexinidazole [330], [331]
MR005477 Fexinidazole sulfoxide metabolite (M1) Fexinidazole sulfone metabolite (M2) Oxidation - Oxidationn Fexinidazole [330], [331]
MR009091 Fidarestat Fidarestat Metabolite F1 Multi-steps Reaction - Oxidation; deamination Fidarestat [509], [290]
MR009091 Fidarestat Fidarestat Metabolite F1 Multi-steps Reaction - Oxidation; deamination Fidarestat [509], [290]
MR001051 Flecainide acetate Meta-O-dealkylated flecainide Oxidation - Meta-O-Dealkylation Flecainide acetate [510], [197]
MR001052 Flecainide acetate Meta-O-dealkylated lactam Oxidation - Meta-O-Dealkylation Flecainide acetate [510], [197]
MR001054 Flibanserin 6-hydroxy-flibanserin-6-sulfate Oxidation - Deamination Flibanserin [511], [198]
MR013906 Flunarizine Flunarizine M2 Oxidation - Hydroxylation Flunarizine [13]
MR005012 Fluoxetine hydrochloride Norfluoxetine Oxidation - N-demethylation Fluoxetine hydrochloride [40], [13], [99], [512]
MR005030 Fluphenazine decanoate Fluphenazine sulfoxide Oxidation - S-oxidation Fluphenazine decanoate [16]
MR005031 Fluphenazine enanthate Fluphenazine sulfoxide Oxidation - S-oxidation Fluphenazine enanthate [16]
MR001063 Fluvastatin sodium 5-hydroxyfluvastatin Oxidation - 5-Hydroxylation Fluvastatin sodium [13], [513]
MR001065 Fluvastatin sodium 5-OH-fluvastatin Oxidation - Hydroxylation Fluvastatin sodium [13], [514], [515]
MR010936 Fluvoxamine Fluvoxamino alcohol Unclear - Unclear Fluvoxamine [24]
MR001079 Fluvoxamine maleate Fluvoxamine alcohol Oxidation - O-Dealkylation Fluvoxamine maleate [24]
MR002944 Formoterol O-demethylated formoterol Oxidation - O-demethylation Formoterol [430], [69]
MR012034 Fruquintinib M409-1 Unclear - Unclear fruquintinib [516], [291]
MR012015 Fruquintinib M379-1 Unclear - Unclear fruquintinib [517], [291]
MR012023 Fruquintinib M409-2 Oxidation - Mono-oxidation fruquintinib [518], [291]
MR012033 Fruquintinib M409-4 Oxidation - Mono-oxidation fruquintinib [519], [291]
MR006109 Deshydroxyethyl opipramol N-acetyl opipramol Oxidation - Oxidationn G-33040 [520]
MR006108 G-33040 Deshydroxyethyl opipramol Oxidation - Decarboxylation G-33040 [520]
MR006110 G-33040 Oxidation product of the hydroxyethyl moiety Oxidation - Oxidationn G-33040 [520]
MR006112 G-33040 Opipramol-N-oxide Oxidation - Oxidationn G-33040 [520]
MR006113 G-33040 Dibenzazepine Oxidation - Oxidationn G-33040 [520]
MR006111 Oxidation product of the hydroxyethyl moiety Decarboxylation product Oxidation - Decarboxylation G-33040 [520]
MR001110 Galantamine hydrobromide O-desmethyl-galantamine Oxidation - O-Demethylation Galantamine hydrobromide [521], [18]
MR011675 Ganaxolone 16-OH ganazolone Oxidation - Hydroxylation Ganaxolone [522]
MR007229 Gliquidone Unclear Unclear - Unclear Gliquidone [523]
MR010767 Glycopyrrolate Glycopyrrolate Metabolite M9 Unclear - Unclear Glycopyrrolate [524]
MR006129 GTPL7557 Pipotiazine sulfoxyde Oxidation - Sulfoxidation GTPL7557 [525], [367]
MR007241 Guanoxan Unclear Oxidation - Hydrolyzationn Guanoxan [55]
MR005083 Halothane 2-chloro-1,1-difluoroethene Reduction - Dehalogenation Halothane [55], [424]
MR005084 Halothane 1-chloro-2,2,2-trifluoroethanide Reduction - Dehalogenation Halothane [55], [424]
MR006056 Fexinidazole Sulfone M1 Fexinidazole Sulfone M2 Oxidation - Oxidationn HOE-239 [330]
MR006055 HOE-239 Fexinidazole Sulfone M1 Oxidation - Oxidationn HOE-239 [330]
MR011201 Hydrocodone Hydromorphone Oxidation - O-demethylation Hydrocodone [526]
MR005118 6-alpha-hydrocodol 6-alpha-hydromorphol Oxidation - O-demethylation Hydrocodone bitartrate [527]
MR005116 6-beta-hydrocodol 6-beta-hydromorphol Oxidation - O-demethylation Hydrocodone bitartrate [527]
MR005109 Hydrocodone bitartrate Hydromorphone Oxidation - O-demethylation Hydrocodone bitartrate [15]
MR012185 Hydroxychloroquine Monodesethylchloroquine Unclear - Unclear Hydroxychloroquine [528], [224]
MR012963 Ibrutinib PCI-45227 (M37) Multi-steps Reaction - Epoxidation; hydrolyzation Ibrutinib [19]
MR005774 Iclaprim Unclear Unclear - Unclear Iclaprim [201]
MR012970 GS-563117 Idelalisib Metabolite M19 Unclear - Unclear Idelalisib [7]
MR004665 Iloperidone Iloperidone P95 Oxidation - Hydrolyzationn Iloperidone [529]
MR012008 Imatinib Other imatinib metabolites Unclear - Unclear Imatinib [530]
MR004669 Imatinib mesylate N-Desmethylimatinib Oxidation - N-demethylation Imatinib mesylate [13], [531], [532]
MR012987 Desipramine 2-hydroxydesipramine Oxidation - Hydrolyzationn Imipramine hydrochloride [533]
MR012989 Imipramine hydrochloride 2-hydroxyimipramine Oxidation - 2-hydroxylation Imipramine hydrochloride [40]
MR001175 Imrecoxib Imrecoxib metabolite M1 Unclear - Unclear Imrecoxib [269], [534]
MR001173 Imrecoxib metabolite M1 Imrecoxib metabolite M2 Unclear - Unclear Imrecoxib [269], [534]
MR011241 N-desacetylIndiplon N-desmethyl-desacetyl-Indiplon Oxidation - N-demethylation indiplon [535]
MR003497 Ipecac Cephaeline Oxidation - Demethylation Ipecac [405], [536]
MR003499 Ipecac 9-O-demethylemetine Oxidation - Demethylation Ipecac [405], [536]
MR012487 JI-101 JI-101 M1 Oxidation - Dihydroxylation JI-101 [355]
MR001351 Ketoconazole ketone hydroxyl intermediate M2 (Ketoconazole) Oxidation - N-Dealkylation Ketoconazole [20]
MR008874 Lasofoxifene 7-hydroxy-lasofoxifene (7-OHLAS) Oxidation - 7-hydroxylation Lasofoxifene [71]
MR003108 Lesinurad Lesinurad metabolite M3 Oxidation - Hydroxylation Lesinurad [104]
MR001444 Letermovir . Unclear - Unclear Letermovir [105]
MR010686 Levallorphan Levallorphan Metabolite M8 Unclear - Unclear Levallorphan [168]
MR010688 Levallorphan Levallorphan Metabolite M4 Unclear - Unclear Levallorphan [168]
MR010687 Levallorphan Metabolite M8 Levallorphan Metabolite M9 Unclear - Unclear Levallorphan [168]
MR001505 Levomilnacipran N-desethyl LVM Oxidation - Desmethylation Levomilnacipran [537]
MR001555 Lidocaine . Unclear - Unclear Lidocaine [29]
MR005383 Linalool 8-hydroxy-linalool Oxidation - Oxidationn Linalool [412], [413], [414]
MR005385 Linalool 6,7-Epoxy-linalool Unclear - Unclear Linalool [413]
MR006888 D-amphetamine Norephedrine Oxidation - Oxidationn Lisdexamfetamine [107]
MR001583 Lofexidine N-(2-aminoethyl)-2-(2,6-dichlorophenoxy)propanamide Oxidation - Hydroxylation Lofexidine [280]
MR001581 N-(2-aminoethyl)-2-(2,6-dichlorophenoxy)propanamide 2,6-dichlorophenol Oxidation - Oxidative Deamination Lofexidine [280]
MR001582 N-(2-aminoethyl)-2-(2,6-dichlorophenoxy)propanamide 2-(2,6-dichlorophenoxy) propionic acid Oxidation - Oxidative Deamination Lofexidine [280]
MR006895 Loperamide hydrochloride N-demethyl loperamide Oxidation - N-demethylation Loperamide hydrochloride [171]
MR006901 Loratadine Desloratadine Oxidation - Oxidationn Loratadine [538]
MR006906 Lorcaserin N-hydroxylorcaserin Oxidation - Hydrolyzationn Lorcaserin [73]
MR006908 Lorcaserin 5-Hydroxylorcaserin Oxidation - Hydrolyzationn Lorcaserin [73]
MR006909 Lorcaserin 7-Hydroxylorcaserin Oxidation - Hydrolyzationn Lorcaserin [73]
MR005870 Lorpiprazole Unclear Unclear - Unclear Lorpiprazole [418]
MR006922 beta-hydroxy acid of lovastatin 6'-beta-Hydroxylovastatin Oxidation - Hydrolyzationn Lovastatin [172]
MR006925 Loxapine succinate Loxapine N-oxide Oxidation - Oxidationn Loxapine succinate [130]
MR006926 Loxapine succinate 7-Hydroxyloxapine Oxidation - Oxidationn Loxapine succinate [130]
MR004573 LU-AE58054 LU-AE58054 Metabolite M1 Unclear - Unclear LU-AE58054 [306]
MR012667 LY-2603618 LY-2603618 Metabolite H2 Oxidation - Hydroxylation LY-2603618 [356]
MR012669 LY-2603618 LY-2603618 Metabolite H3 Oxidation - Hydroxylation LY-2603618 [356]
MR003762 LY-450139 LY-2484595 Metabolite M3 Oxidation - Benzylic hydroxylation LY-450139 [307]
MR013358 ID-11614 ID15002 Unclear - Unclear M-813 [539]
MR013358 ID-11614 ID15002 Unclear - Unclear M-813 [539]
MR013358 ID-11614 ID15002 Unclear - Unclear M-813 [539]
MR013363 M-813 M-813 Metabolite MX1 Unclear - Unclear M-813 [539], [540]
MR013440 Maprotiline hydrochloride 2-OH-maprotiline Oxidation - Aromatic hydroxylation Maprotiline hydrochloride [24]
MR013439 Maprotiline hydrochloride 3-OH-maprotiline Oxidation - Aromatic hydroxylation Maprotiline hydrochloride [24]
MR013438 Maprotiline hydrochloride Desmethylmaprotiline Oxidation - N-demethylation Maprotiline hydrochloride [24]
MR001610 Meclizine Norchlorcyclizine Oxidation - Hydroxylation Meclizine [174]
MR001611 Meclizine Meclizine metabolite M1 Oxidation - Hydroxylation Meclizine [174]
MR001612 Meclizine Meclizine metabolite M2 Oxidation - Benzylic Oxidation Meclizine [174]
MR005828 Mequitazine Mequitazine S-oxide Oxidation - S-oxidation Mequitazine [416]
MR005829 Mequitazine Hydroxy-Mequitazine Oxidation - Hydrolyzationn Mequitazine [416]
MR009984 Metamfetamine Amphetamine Unclear - Unclear Metamfetamine [541], [542], [543]
MR009991 Metamfetamine p-hydroxymethamphetamine Unclear - Unclear Metamfetamine [543], [544]
MR009998 Methadone EDDP Oxidation - N-demethylation Methadone [175], [545]
MR010000 Methamphetamine hydrochloride Amphetamine Unclear - Unclear Methamphetamine hydrochloride [541], [542], [543]
MR010007 Methamphetamine hydrochloride p-hydroxymethamphetamine Unclear - Unclear Methamphetamine hydrochloride [543], [544]
MR005819 Methoxyamphetamine beta 4-hydroxyamphetamine Oxidation - #NAME? Methoxyamphetamine beta [410], [546]
MR005816 Methoxybufotenin Bufotenine Oxidation - O-demethylation Methoxybufotenin [417]
MR013390 Ethylphenidate Ethyl 3-amino-6-oxo-2-phenylhexanoate Unclear - Unclear Methylphenidate [9]
MR013395 Metoclopramide hydrochloride Metoclopramide hydrochloride Metabolite M4 Oxidation - Oxidationn Metoclopramide hydrochloride [547]
MR013401 Metoclopramide hydrochloride Metoclopramide hydrochloride Metabolite M3 Oxidation - N-dealkylation Metoclopramide hydrochloride [547]
MR013406 Metoclopramide hydrochloride Metoclopramide hydrochloride Metabolite M10 Oxidation - Nitration Metoclopramide hydrochloride [547]
MR013397 Metoclopramide hydrochloride Monodeethylmetoclopramide Unclear - Unclear Metoclopramide hydrochloride [548], [549], [21]
MR004713 Metoprolol succinate O-Demethylmetoprolol Oxidation - O-dealkylation Metoprolol succinate [424]
MR004707 Metoprolol succinate Alpha-Hydroxymetoprolol Oxidation - Hydrolyzationn Metoprolol succinate [550]
MR004722 Metoprolol tartrate O-Demethylmetoprolol Oxidation - O-dealkylation Metoprolol tartrate [424]
MR004716 Metoprolol tartrate Alpha-Hydroxymetoprolol Oxidation - Hydrolyzationn Metoprolol tartrate [551]
MR004735 Mexiletine hydrochloride 2-hydroxymexiletine Oxidation - 2-hydroxylation Mexiletine hydrochloride [552]
MR004737 Mexiletine hydrochloride p-hydroxymexiletine Oxidation - Hydrolyzationn Mexiletine hydrochloride [552]
MR001673 Mianserin (R)-mianserin,N-Desmethyl Oxidation - N-Dealkylation Mianserin [24]
MR001669 Mianserin 8-hydroxyminaserin Oxidation - Hydroxylation Mianserin [24]
MR001672 Mianserin (R)-mianserin,8-hydroxy Oxidation - Hydroxylation Mianserin [24]
MR001668 N-desmethylmianserin 8-hydroxy-N-desmethylmianserin Oxidation - 8-Hydroxylation Mianserin [24]
MR004749 Desglymidodrine Midodrine Metabolite M-2 Oxidation - 5'-O-demethylation Midodrine [553]
MR001685 Milnacipran N-Desethyl milnacipran Oxidation - Desethylation Milnacipran [281]
MR001695 Minaprine Minaprine metabolite M3 Oxidation - Hydroxylation Minaprine [554]
MR004787 Mirtazapine 8-hydroxymirtazapine Oxidation - 8-hydroxylation Mirtazapine [555]
MR006059 MJ-13105 5-hydroxybucindolol Oxidation - Hydrolyzationn MJ-13105 [556]
MR007630 ML-3000 Licofelone M4 Oxidation - Hydrolyzationn ML-3000 [13]
MR009723 Motesanib Motesanib M5 Oxidation - Hydroxylation Motesanib [383]
MR009726 Motesanib Motesanib M4 Unclear - Unclear Motesanib [383], [557]
MR009732 Motesanib Motesanib M3 Unclear - Unclear Motesanib [383]
MR012777 MP-513 MP-513 Metabolite M1 Oxidation - Thiazolidine-1-oxidation MP-513 [375], [376]
MR012780 MP-513 MP-513 Metabolite M4 Oxidation - Oxidationn MP-513 [375]
MR005404 MRTX849 Unclear Unclear - Unclear MRTX849 [558]
MR003383 R-Naftopidil R-Naftopidil metabolite M2 Unclear - Unclear Naftopidil [559], [560]
MR003387 S-Naftopidil R-Naftopidil metabolite M3 Unclear - Unclear Naftopidil [559], [560]
MR008825 Nalbuphine 3'-hydroxynalbuphine Oxidation - Hydroxylation Nalbuphine [133]
MR003787 NE-10064 NE-10064 Metabolite M5 Unclear - Unclear NE-10064 [300]
MR013408 Nebivolol hydrochloride 4-hydroxy Nebivolol Oxidation - 4-hydroxylation Nebivolol hydrochloride [561]
MR009257 N-despropyl-rotigotine Neupro Metabolite M2 Unclear - Unclear Neupro [562], [259]
MR009255 Neupro N-despropyl-rotigotine Unclear - Unclear Neupro [562], [259]
MR003269 Nevirapine 12-hydroxynevirapine Oxidation - Hydroxylation Nevirapine [563], [564], [565]
MR003271 Nevirapine 8-hydroxynevirapine Oxidation - 8-Hydroxylation Nevirapine [566]
MR001730 Nicardipine hydrochloride Dehydronicardipine Oxidation - Heteroring Dehydrogenation Nicardipine hydrochloride [424], [55], [204]
MR001732 I-OHMMDL MDL Oxidation - N-Demethylation Nicergoline [567]
MR001794 Desmethylnortriptyline E-10-hydroxydesmethylnortriptyline Oxidation - N-Demethylation Nortriptyline hydrochloride [13], [568]
MR001796 Nortriptyline hydrochloride Desmethylnortriptyline Unclear - Unclear Nortriptyline hydrochloride [569], [570]
MR013882 Nuplazid AC-279 Unclear - Unclear Nuplazid [360]
MR001804 Olanzapine 2-hydroxymethylolanzapine Unclear - Unclear Olanzapine [571], [572], [573]
MR012109 Omecamtiv mecarbil Omecamtiv mecarbil Metabolites M3 Unclear - Unclear Omecamtiv mecarbil [295]
MR012106 Omecamtiv mecarbil Omecamtiv mecarbil Metabolites M5 Unclear - Unclear Omecamtiv mecarbil [295]
MR001836 Ondansetron 7-OH-ondansetron Oxidation - Hydroxylation Ondansetron [24], [574]
MR001839 Ondansetron 8-OH-ondansetron Oxidation - Hydroxylation Ondansetron [24]
MR001840 Ondansetron 6-OH-ondansetron Oxidation - Hydroxylation Ondansetron [574]
MR006393 OPC-12759 6-Hydroxyrebamipide Unclear - Unclear OPC-12759 [315]
MR001843 Org-33062 3'-OH-gepirone Unclear - Unclear Org-33062 [575]
MR001844 Org-33062 5-OH-gepirone Unclear - Unclear Org-33062 [575]
MR013819 Noroxycodone Noroxymorphone Unclear - Unclear Oxycodone [576]
MR013820 Oxycodone Oxymorphone Unclear - Unclear Oxycodone [576]
MR001884 Oxycodone hydrochloride Oxymorphone Oxidation - O-Demethylation Oxycodone hydrochloride [134], [577], [578], [579]
MR001902 Oxymorphone Alpha-Oxycodol Reduction - 6-Ketoreduction Oxymorphone [48]
MR001903 Oxymorphone 6beta-Oxycodol Reduction - 6-Ketoreduction Oxymorphone [48]
MR001904 Oxymorphone 6beta-Oxymorphol Oxidation - N-Demethylation Oxymorphone [48]
MR001905 Oxymorphone Oxymorphone Oxidation - O-Demethylation Oxymorphone [48]
MR001924 Paliperidone 9-hydroxyrisperidone Unclear - Unclear Paliperidone [580]
MR001925 Paliperidone Risperidone Oxidation - Dehydrogenation Paliperidone [581]
MR002864 Palonosetron hydrochloride Palonosetron metabolite M4 Oxidation - Hydroxylation Palonosetron hydrochloride [582]
MR002865 Palonosetron hydrochloride Palonosetron metabolite M9 Oxidation - N-Oxidation Palonosetron hydrochloride [582]
MR001937 Panobinostat lactate Panobinostat lactate metabolite M5 Unclear - Unclear Panobinostat lactate [58]
MR003337 Paroxetine hydrochloride Paroxetine catechol Unclear - Unclear Paroxetine hydrochloride [13], [583]
MR001948 Pazopanib Pazopanib hydrochloride Oxidation - Hydroxylation; N-Demethylation Pazopanib [136], [584], [585]
MR008356 PD-143188 PD-147693 Oxidation - Hydroxylation PD-143188 [341]
MR008357 PD-147693 PD-155144 Oxidation - Hydroxylation PD-143188 [341]
MR008364 PD-147693 PD-163637 Conjugation - Sulfation PD-143188 [341]
MR008361 PD-149394 PD-155144 Oxidation - Hydroxylation PD-143188 [341]
MR008362 PD-155144 PD-163639 Unclear - Unclear PD-143188 [341]
MR008363 PD-163639 PD-163249 Unclear - Unclear PD-143188 [341]
MR008363 PD-163639 PD-163249 Unclear - Unclear PD-143188 [341]
MR008359 PD-163640 PD-163249 Unclear - Unclear PD-143188 [341]
MR008359 PD-163640 PD-163249 Unclear - Unclear PD-143188 [341]
MR002005 Perphenazine N-Dealkylated perphenazine Oxidation - N-Dealkylation Perphenazine [586]
MR002006 Perphenazine Perphenazine sulfoxide Oxidation - S-Oxidation Perphenazine [424]
MR013716 PF-00734200 PF-00734200 metabolite M5 Unclear - Unclear PF-00734200 [332]
MR002014 Acetaminophen NAPQI Oxidation - Oxidation Phenacetin [587]
MR002030 Hydroxyphenytoin Phenytoin catechol Oxidation - Oxidation Phenytoin [40]
MR002036 Phenytoin Phenytoin dihydrodiol Oxidation - Dihydroxylation; Oxidation Phenytoin [13]
MR002038 Pimozide DHBPI Oxidation - N-Dealkylation Pimozide [588]
MR002040 Pimozide 5-hydroxypimozide Oxidation - Hydroxylation Pimozide [588]
MR002041 Pimozide 6-hydroxypimozide Oxidation - Hydroxylation Pimozide [588]
MR002059 Piperazine N-mononitrosopiperazine Unclear - Unclear Piperazine [239], [589]
MR008868 Pitavastatin Pitavastatin metabolite M-13 Oxidation - Oxidation Pitavastatin [590]
MR008867 Pitavastatin Pitavastatin metabolite M-14 Oxidation - Oxidation Pitavastatin [590]
MR011133 Pitolisant BP2.941 Oxidation - Hydroxylation Pitolisant [591]
MR011134 Pitolisant BP2.951 Conjugation - Glycine conjugation Pitolisant [592]
MR002083 Ponatinib hydrochloride AP24567 Oxidation - N-Demethylation Ponatinib hydrochloride [138], [593], [594]
MR002142 Primaquine 2OH-PQ Oxidation - Hydroxylation Primaquine [595], [596]
MR002143 Primaquine 3OH-PQ Oxidation - Hydroxylation Primaquine [595], [596]
MR002144 Primaquine 4OH-PQ Oxidation - Hydroxylation Primaquine [595], [596]
MR002146 Primaquine 5OH-PQ Oxidation - Hydroxylation Primaquine [596]
MR008085 Prinomastat Pyridine N-oxide metabolite Unclear - Unclear Prinomastat [240]
MR002156 Procainamide hydrochloride N-Acetyl-3-hydroxyprocainamide Oxidation - N-Hydroxylation Procainamide hydrochloride [180], [597]
MR002166 Prochlorperazine N-demethylation Oxidation - N-Demethylation Prochlorperazine [598], [599], [600]
MR002167 Prochlorperazine Prochlorperazine sulfoxide Oxidation - Sulfoxidation Prochlorperazine [598], [599], [600]
MR002168 Prochlorperazine Prochlorperazine 7-hydroxide Oxidation - 7-Hydroxylation Prochlorperazine [598], [599], [600]
MR002172 Progesterone 11-deoxycorticosterone Oxidation - Hydroxylation Progesterone [601]
MR002182 Promethazine Promethazine Hydroxy metabolite Oxidation - Hydroxylation Promethazine [602], [603], [604]
MR002879 Propafenone hydrochloride 5-hydroxypropafenone Oxidation - 5-Hydroxylation Propafenone hydrochloride [78], [605]
MR002881 Propafenone hydrochloride (S)-5-hydroxypropafenone Oxidation - Hydroxylation Propafenone hydrochloride [424]
MR002883 Propafenone hydrochloride (S)-4'-hydroxypropafenone Oxidation - Hydroxylation Propafenone hydrochloride [424]
MR002195 Propranolol hydrochloride 4'-hydroxypropanolol Oxidation - 4-Hydroxylation Propranolol hydrochloride [606], [607]
MR013648 PT2385 PT2385 M10 Oxidation - Hydroxylation PT2385 [342]
MR013646 PT2385 PT2385 M2 Oxidation - Hydroxylation PT2385 [342]
MR012497 PTC299 O-Desmethyl emvododstat Unclear - Unclear PTC299 [361]
MR005205 Pyrantel Unclear Unclear - Unclear Pyrantel [22]
MR006986 Q-100155 9-O-demethylemetine Oxidation - Demethylation Q-100155 [608]
MR006987 Q-100155 10-O-demethylemetine Oxidation - Demethylation Q-100155 [608]
MR002204 Quetiapine fumarate 7-hydroxyquetiapine Oxidation - Hydroxylation Quetiapine fumarate [609], [610]
MR010018 Quinine sulfate Quinine sulfate Metabolite M3 Oxidation - Demethylation Quinine sulfate [611]
MR006424 R-1124 Netupitant N-Oxide Oxidation - Oxidationn R-1124 [612]
MR006425 R-1124 N\demethylated netupitant Oxidation - Demethylation R-1124 [612]
MR006426 R-1124 Monohydroxy netupitant Oxidation - Hydrolyzationn R-1124 [612]
MR007661 R-58735 6-hydroxylation of sabeluzole Oxidation - 6-hydroxylation R-58735 [397]
MR005213 Ramosetron Unclear Unclear - Unclear Ramosetron [284]
MR013046 Ranitidine Desmethylranitidine Oxidation - N-demethylation Ranitidine [181]
MR009498 Ranolazine RS-88390 (CVT-2514) Oxidation - O-demethylation Ranolazine [613], [614]
MR009500 Ranolazine CVT-2534 Oxidation - N-dealkylation Ranolazine [613]
MR009504 Ranolazine CVT-2551 Oxidation - Hydroxylation Ranolazine [613]
MR009506 Ranolazine CVT-2738 Oxidation - N-dealkylation Ranolazine [613], [615]
MR009508 Ranolazine CVT-2512 Conjugation - O-arylation Ranolazine [613]
MR009509 Ranolazine CVT-3369 Hydrolysis - Hydrolysis Ranolazine [613]
MR013218 Remdesivir Remdesivir M1 Unclear - Unclear Remdesivir [60]
MR005235 Remoxipride Unclear Unclear - Unclear Remoxipride [55]
MR006357 Repinotan Unclear Unclear - Unclear Repinotan [419]
MR009530 Revefenacin Unclear Unclear - Unclear Revefenacin [113]
MR008674 Ripretinib DP-5439 Unclear - Unclear Ripretinib [616]
MR009549 Risperidone 9-hydroxyrisperidone Oxidation - 9-hydroxylation Risperidone [617]
MR009550 Ritonavir N-Desmethylritonavir Oxidation - N-demethylation Ritonavir [13]
MR006427 RO-111163 Moclobemide M1 Oxidation - C-oxidation RO-111163 [618]
MR006433 RO-111163 Moclobemide M5 Oxidation - N-oxidation RO-111163 [618]
MR006435 RO-111163 Moclobemide M3 Oxidation - Aromatic hydroxylation RO-111163 [618]
MR006436 RO-111163 Moclobemide M9 Oxidation - Oxidationn deamination RO-111163 [618]
MR009604 Roxatidine M5 Roxatidine M2 Unclear - Unclear Roxatidine [339]
MR009605 Roxatidine M5 Roxatidine M3 Unclear - Unclear Roxatidine [339]
MR006438 RSD-1235 RSD-1385 Oxidation - 4-O-demethylation RSD-1235 [316]
MR002210 Rucaparib Rucaparib M323 metabolite Oxidation - Oxidation Rucaparib [114]
MR002211 Rucaparib Rucaparib M324 metabolite Oxidation - Oxidation Rucaparib [114], [619]
MR002212 Rucaparib Rucaparib M309 metabolite Oxidation - N-Demethylation Rucaparib [114]
MR002213 Rucaparib Rucaparib M337b metabolite Oxidation - Oxidation Rucaparib [114]
MR003173 CGP 47292 CGP 47292-beta-d-glucuronide Conjugation - Glucuronidation Rufinamide [620]
MR012411 Saracatinib Saracatinib M2 Unclear - Unclear Saracatinib [350]
MR012412 Saracatinib Saracatinib M3 Unclear - Unclear Saracatinib [350]
MR012413 Saracatinib Saracatinib M4 Unclear - Unclear Saracatinib [350]
MR010185 Savolitinib Savolitinib Metabolite M2 Unclear - Unclear Savolitinib [621]
MR010842 Methamphetamine Amphetamine Unclear - Unclear Selegiline [209]
MR002890 Selegiline hydrochloride Levmetamfetamine Oxidation - N-Dealkylation Selegiline hydrochloride [622]
MR013881 SEP-363856 SEP-383103 Unclear - Unclear SEP-363856 [321]
MR005254 4-hydroxy-serindole Dehydrosertindole Oxidation - Oxidationn Sertindole [623]
MR005250 5-hydroxy-serindole Dehydrosertindole Oxidation - Oxidationn Sertindole [623]
MR005252 Dehydrosertindole Norsertindole Oxidation - N-dealkylation Sertindole [623]
MR005252 Dehydrosertindole Norsertindole Oxidation - N-dealkylation Sertindole [623]
MR005259 Sertindole Norsertindole Oxidation - N-dealkylation Sertindole [623], [624]
MR002247 Sertraline hydrochloride Desmethylsertraline Oxidation - N-Demethylation Sertraline hydrochloride [625], [626], [627], [628]
MR013895 Sildenafil N-desmethyl Sildenafil Unclear - Unclear Sildenafil [629], [322], [630]
MR002252 Sildenafil citrate Desmethylsildenafil Oxidation - N-Demethylation Sildenafil citrate [631], [632], [633]
MR002253 Sildenafil citrate N-dealkyl Sildenafil Oxidation - N-Dealkylation Sildenafil citrate [13]
MR013434 Simvastatin 6'-beta-Hydroxysimvastatin Oxidation - Aliphatic hydroxylation Simvastatin [424]
MR006826 Solifenacin succinate 4R-hydroxy solifenacin Oxidation - Hydrolyzationn Solifenacin succinate [145]
MR005888 Sparteine 2,3-didehydrosparteine Unclear - Unclear Sparteine [634]
MR004040 SQ-109 SQ-109 Metabolite M1 Oxidation - N-Nitrosylation SQ-109 [340]
MR004044 SQ-109 SQ-109 Metabolite M4-2 Multi-steps Reaction - Ring oxidation; Epoxidation; rearrangement SQ-109 [340]
MR004045 SQ-109 SQ-109 Metabolite M4-1 Oxidation - Ring oxidation; N-hydroxylation SQ-109 [340]
MR010641 N-Desmethyl sumatriptan N-Desmethyl sumatriptan Unclear - Unclear Sumatriptan [146]
MR010640 Sumatriptan N-Desmethyl sumatriptan Unclear - Unclear Sumatriptan [146]
MR010647 Sumatriptan Sumatriptan N-oxide Unclear - Unclear Sumatriptan [146]
MR002899 Tacrine hydrochloride 7-hydroxytacrine Oxidation - Hydroxylation Tacrine hydrochloride [24]
MR002330 Tafenoquine 5,6-ortho-quinone Hydrolysis - Hydrolysis Tafenoquine [635], [245]
MR009360 TAK-802 TAK-802 Metabolite M-III Unclear - Unclear TAK-802 [387]
MR003516 N-Desmethyltamoxifen Endoxifen Oxidation - 4-Hydroxylation Tamoxifen citrate [636]
MR003510 Tamoxifen citrate N-Desmethyltamoxifen Oxidation - N-Dealkylation Tamoxifen citrate [637], [638], [639], [640], [641]
MR003526 Tamoxifen citrate 4-hydroxytamoxifen Oxidation - 4-Hydroxylation Tamoxifen citrate [637], [638], [639], [642]
MR003424 Tamsulosin Tamsulosin M-3 metabolite Oxidation - Hydroxylation Tamsulosin [643], [644]
MR003425 Tamsulosin Tamsulosin M-4 metabolite Oxidation - Demethylation Tamsulosin [643], [644]
MR008816 Tandospirone 1\(2\pyrimidinyl)\piperazine (1\PP) Oxidation - Oxidative cleavage Tandospirone [645], [147]
MR008818 Tandospirone Tandospirone metabolite Ma Unclear - Unclear Tandospirone [147]
MR008820 Tandospirone Tandospirone metabolite M2 Oxidation - Hydroxylation Tandospirone [147]
MR008822 Tandospirone Tandospirone metabolite M4 Oxidation - Hydroxylation Tandospirone [147]
MR002335 Tapentadol hydroxy tapentado Oxidation - Hydroxylation Tapentadol [116]
MR002340 Tasimelteon Tasimelteon metabolite M13 Oxidation - Hydroxylation Tasimelteon [646]
MR002338 Tasimelteon metabolite M13 Tasimelteon metabolite M9 Unclear - Unclear Tasimelteon [646]
MR002360 Tegaserod O-desmethyl tegaserod Unclear - Unclear Tegaserod [117]
MR004909 Alpha-dihydrotetrabenazine 9-desmethyl-alpha-DHTBZ Unclear - Unclear Tetrabenazine [647]
MR004908 Tetrabenazine Alpha-dihydrotetrabenazine Unclear - Unclear Tetrabenazine [647]
MR004957 Thioridazine Thioridazine 2-sulfoxide Oxidation - S-oxidation Thioridazine [648]
MR004987 Ticlopidine Ticlopidine S-oxide Unclear - Unclear Ticlopidine [13]
MR004995 M1 metabolite, timolol Timolol maleate Metabolite M4 Unclear - Unclear Timolol maleate [649]
MR004996 M1 metabolite, timolol Timolol maleate Metabolite M3 Unclear - Unclear Timolol maleate [649]
MR004997 Timolol maleate Timolol maleate Metabolite M2 Unclear - Unclear Timolol maleate [649]
MR004994 Timolol maleate M1 metabolite, timolol Oxidation - Hydrolyzationn Timolol maleate [649], [650]
MR010765 Tiotropium Dithienylglycolic Acid Unclear - Unclear Tiotropium [651], [213]
MR010766 Tiotropium N-methylscopine Unclear - Unclear Tiotropium [651], [213]
MR005003 Tipranavir Tipranavir Metabolite Oxidation - Monohydroxylation Tipranavir [652]
MR006783 5-Hydroxymethyl tolterodine 5-Carboxylic acid tolterodine Unclear - Unclear Tolterodine tartrate [13]
MR003377 N-Desmethyltramadol N,O-didesmethyltramadol Oxidation - O-Demethylation Tramadol hydrochloride [40]
MR003374 O-Desmethyltramadol N,O-didesmethyltramadol Oxidation - N-Demethylation Tramadol hydrochloride [40]
MR003380 Tramadol hydrochloride O-Desmethyltramadol Oxidation - O-Demethylation Tramadol hydrochloride [653], [654]
MR002909 TCBZ-SX Triclabendazole sulfone metabolite Oxidation - Oxidation Triclabendazole [655], [656]
MR002909 TCBZ-SX Triclabendazole sulfone metabolite Oxidation - Oxidation Triclabendazole [655], [656]
MR002458 Trimethoprim 3-Desmethyl-TMP Oxidation - O-Demethylation Trimethoprim [657]
MR006220 Tropisetron 5-hydroxy tropisetron Oxidation - Hydrolyzationn Tropisetron [658], [659], [660]
MR006221 Tropisetron 6-hydroxy tropisetron Oxidation - Hydrolyzationn Tropisetron [658], [659], [660]
MR006222 Tropisetron 7-hydroxy tropisetron Oxidation - Hydrolyzationn Tropisetron [658], [659], [660]
MR006150 TRV-130 Oxy-oliceridine Oxidation - Oxidationn TRV-130 [661]
MR006152 TRV-130 TRV0109662 Oxidation - N-dealkylation TRV-130 [661]
MR009187 TRYPTAMINE Tryptophol Unclear - Unclear TRYPTAMINE [302]
MR002469 PGL4002 PGL-4004 Oxidation - Di-N-Demethylation Ulipristal [217]
MR002471 Ulipristal PGL4002 Oxidation - Mono-N-Demethylation Ulipristal [217]
MR008832 Umeclidinium Umeclidinium M33 Oxidation - Hydroxylation Umeclidinium [219]
MR008834 Umeclidinium Umeclidinium M14 Oxidation - O-dealkylation Umeclidinium [218]
MR013194 Umeclidinium bromide Umeclidinium M14 Oxidation - O-dealkylation Umeclidinium bromide [662]
MR013189 Umeclidinium bromide Umeclidinium M33 Oxidation - Hydroxylation Umeclidinium bromide [662]
MR002472 Upadacitinib . Conjugation - Glucuronidation Upadacitinib [663]
MR005637 Venlafaxine hydrochloride Desvenlafaxine Oxidation - O-demethylation Venlafaxine hydrochloride [664], [665], [666]
MR013238 Vilazodone hydrochloride Vilazodone metabolite M10 Oxidation - Oxidation deamination Vilazodone hydrochloride [154], [667], [668]
MR005673 Vortioxetine hydrobromide Vortioxetine Metabolite 2 Oxidation - Hydrolyzationn Vortioxetine hydrobromide [155], [669]
MR005668 Vortioxetine hydrobromide Vortioxetine Metabolite 1 Oxidation - Hydrolyzationn Vortioxetine hydrobromide [155], [669]
MR005671 Vortioxetine hydrobromide LU-AA39835 Oxidation - Hydrolyzationn Vortioxetine hydrobromide [155], [669]
MR005669 Vortioxetine Metabolite 1 LU-AA34443 Oxidation - Carboxylation Vortioxetine hydrobromide [155], [669]
MR006068 WR-6026 8-(6-ethylaminohexylamino)-6-methoxy-lepidine Unclear - Unclear WR-6026 [670]
MR006069 WR-6026 8-(6-diethylaminohexylamino)-6-methoxy-4-hydroxymethyl quinoline Unclear - Unclear WR-6026 [670]
MR006491 WSM-3978G Monohydroxyperhexiline Oxidation - Hydrolyzationn WSM-3978G [309]
MR006492 WSM-3978G Trans-hydroxyperhexilline Oxidation - Aliphatic hydroxylation WSM-3978G [309]
MR012201 YM-17E YM-17E M1 Unclear - Unclear YM-17E [393]
MR012494 Precursor AS2036313-00 Other reaction - Deprotonation YM-758 [354]
MR012493 YM-758 Precursor Oxidation - Hydroxylation YM-758 [354]
MR005676 Zidovudine 3'-Aminothymidine Reduction - Reduction Zidovudine [55], [185]
MR005696 Zolpidem tartrate Methoxyzolpidem derivative (M3) Oxidation - Methyl-hydroxylation Zolpidem tartrate [13], [671]
MR005702 Zolpidem tartrate Methoxyzolpidem Oxidation - Aliphatic hydroxylation Zolpidem tartrate [13], [671]
MR005698 Zolpidem tartrate Methoxyzolpidem derivative (M4) Oxidation - Methyl-hydroxylation; oxidation Zolpidem tartrate [13], [671]
MR013085 Zotepine Zotepine S-oxide Oxidation - S-oxidation Zotepine [24]
⏷ Show the Full List of 554 MR(s)
Tissue/Disease-Specific Protein Abundances of This DME
      Tissue-specific Protein Abundances in Healthy Individuals Click to Show/Hide
Download the Tissue-Specific Variation(s) Profile
      ICD Disease Classification 01 Infectious/parasitic disease Click to Show/Hide
                  ICD-11: 1C1H     Necrotising ulcerative gingivitis Click to Show/Hide
The Studied Tissue     Gingival tissue
The Specified Disease     Bacterial infection of gingival [ICD-11:1C1H]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.83E-01; Fold-change: -1.74E-02; Z-score: -7.78E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 1E30     Influenza Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Influenza [ICD-11:1E30]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.29E-04; Fold-change: 4.43E-01; Z-score: 1.04E+01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 1E51     Chronic viral hepatitis Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Chronic hepatitis C [ICD-11:1E51.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.31E-01; Fold-change: 1.04E-01; Z-score: 8.98E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 1G41     Sepsis with septic shock Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Sepsis with septic shock [ICD-11:1G41]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.79E-01; Fold-change: 7.87E-02; Z-score: 2.63E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: CA40     Respiratory syncytial virus infection Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Pediatric respiratory syncytial virus infection [ICD-11:CA40.11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.24E-04; Fold-change: -1.83E-01; Z-score: -1.21E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: CA42     Rhinovirus infection Click to Show/Hide
The Studied Tissue     Nasal epithelium tissue
The Specified Disease     Rhinovirus infection [ICD-11:CA42.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 6.00E-01; Fold-change: -7.71E-03; Z-score: -5.19E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: KA60     Neonatal sepsis Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Neonatal sepsis [ICD-11:KA60]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.68E-02; Fold-change: -7.62E-02; Z-score: -2.41E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 02 Neoplasm Click to Show/Hide
                  ICD-11: 2A00     Brain cancer Click to Show/Hide
The Studied Tissue     Nervous tissue
The Specified Disease     Glioblastopma [ICD-11:2A00.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.16E-22; Fold-change: -1.26E-01; Z-score: -5.93E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Brain stem tissue
The Specified Disease     Glioma [ICD-11:2A00.0Y-2A00.0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.73E-01; Fold-change: -1.42E-01; Z-score: -5.35E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     White matter tissue
The Specified Disease     Glioma [ICD-11:2A00.0Y-2A00.0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.09E-09; Fold-change: -9.49E-01; Z-score: -8.32E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Brain stem tissue
The Specified Disease     Neuroectodermal tumour [ICD-11:2A00.11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 3.34E-01; Fold-change: -2.49E-01; Z-score: -7.53E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2A20     Myeloproliferative neoplasm Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Myelofibrosis [ICD-11:2A20.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 3.41E-01; Fold-change: -1.92E-02; Z-score: -2.46E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Whole blood
The Specified Disease     Polycythemia vera [ICD-11:2A20.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.22E-02; Fold-change: -2.51E-02; Z-score: -2.94E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2A36     Myelodysplastic syndrome Click to Show/Hide
The Studied Tissue     Bone marrow
The Specified Disease     Myelodysplastic syndrome [ICD-11:2A36-2A3Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.26E-01; Fold-change: 5.09E-02; Z-score: 2.01E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 1.93E-03; Fold-change: -4.65E-01; Z-score: -4.51E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2A81     Diffuse large B-cell lymphoma Click to Show/Hide
The Studied Tissue     Tonsil tissue
The Specified Disease     Diffuse large B-cell lymphoma [ICD-11:2A81]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.88E-01; Fold-change: -1.28E-01; Z-score: -5.96E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2A83     Plasma cell neoplasm Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Multiple myeloma [ICD-11:2A83.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.28E-01; Fold-change: -3.69E-02; Z-score: -1.61E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Bone marrow
The Specified Disease     Multiple myeloma [ICD-11:2A83.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.35E-01; Fold-change: -5.39E-03; Z-score: -5.20E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2B33     Leukaemia Click to Show/Hide
The Studied Tissue     Bone marrow
The Specified Disease     Acute myelocytic leukaemia [ICD-11:2B33.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.68E-01; Fold-change: 5.03E-03; Z-score: 2.52E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2B6E     Oral cancer Click to Show/Hide
The Studied Tissue     Oral tissue
The Specified Disease     Oral cancer [ICD-11:2B6E]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.10E-11; Fold-change: -3.94E-01; Z-score: -1.97E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 9.89E-01; Fold-change: 2.68E-02; Z-score: 1.03E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2B70     Esophageal cancer Click to Show/Hide
The Studied Tissue     Esophagus
The Specified Disease     Esophagal cancer [ICD-11:2B70]
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 2.63E-01; Fold-change: 1.59E-01; Z-score: 6.06E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
                  ICD-11: 2B72     Stomach cancer Click to Show/Hide
The Studied Tissue     Gastric tissue
The Specified Disease     Gastric cancer [ICD-11:2B72]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.16E-01; Fold-change: -1.10E-01; Z-score: -1.38E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 8.45E-02; Fold-change: 7.74E-02; Z-score: 3.22E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2B90     Colon cancer Click to Show/Hide
The Studied Tissue     Colon tissue
The Specified Disease     Colon cancer [ICD-11:2B90]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.39E-05; Fold-change: -5.40E-02; Z-score: -2.65E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 2.13E-03; Fold-change: -8.16E-02; Z-score: -3.02E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2B92     Rectal cancer Click to Show/Hide
The Studied Tissue     Rectal colon tissue
The Specified Disease     Rectal cancer [ICD-11:2B92]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.98E-01; Fold-change: 1.97E-02; Z-score: 2.59E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 1.19E-01; Fold-change: -9.12E-02; Z-score: -4.83E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C10     Pancreatic cancer Click to Show/Hide
The Studied Tissue     Pancreas
The Specified Disease     Pancreatic cancer [ICD-11:2C10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 6.44E-02; Fold-change: -1.56E-01; Z-score: -4.37E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 2.57E-05; Fold-change: -1.97E-01; Z-score: -4.11E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C12     Liver cancer Click to Show/Hide
The Studied Tissue     Liver tissue
The Specified Disease     Liver cancer [ICD-11:2C12.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.63E-04; Fold-change: -2.52E-01; Z-score: -6.62E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 4.24E-08; Fold-change: -1.43E-01; Z-score: -4.34E-01
The Expression Level of Disease Section Compare with the Other Disease Section     p-value: 2.26E-04; Fold-change: -3.58E-01; Z-score: -5.37E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
Download DME expression data in the tissue of the other disease section
                  ICD-11: 2C25     Lung cancer Click to Show/Hide
The Studied Tissue     Lung tissue
The Specified Disease     Lung cancer [ICD-11:2C25]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.76E-04; Fold-change: -4.73E-02; Z-score: -2.39E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 1.38E-01; Fold-change: -9.66E-03; Z-score: -3.59E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C30     Skin cancer Click to Show/Hide
The Studied Tissue     Skin
The Specified Disease     Melanoma [ICD-11:2C30]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.64E-02; Fold-change: -1.20E-01; Z-score: -3.11E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Skin
The Specified Disease     Skin cancer [ICD-11:2C30-2C3Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.37E-01; Fold-change: -3.80E-02; Z-score: -1.16E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 1.00E-15; Fold-change: 2.76E-01; Z-score: 8.36E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C6Z     Breast cancer Click to Show/Hide
The Studied Tissue     Breast tissue
The Specified Disease     Breast cancer [ICD-11:2C60-2C6Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 6.51E-02; Fold-change: -2.38E-02; Z-score: -9.58E-02
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 1.14E-02; Fold-change: 4.23E-02; Z-score: 2.03E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C73     Ovarian cancer Click to Show/Hide
The Studied Tissue     Ovarian tissue
The Specified Disease     Ovarian cancer [ICD-11:2C73]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.02E-01; Fold-change: -3.26E-02; Z-score: -1.33E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 1.28E-02; Fold-change: 2.40E-01; Z-score: 9.51E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C77     Cervical cancer Click to Show/Hide
The Studied Tissue     Cervical tissue
The Specified Disease     Cervical cancer [ICD-11:2C77]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.95E-01; Fold-change: -2.05E-02; Z-score: -1.41E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C78     Uterine cancer Click to Show/Hide
The Studied Tissue     Endometrium tissue
The Specified Disease     Uterine cancer [ICD-11:2C78]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 3.27E-02; Fold-change: -6.33E-02; Z-score: -2.52E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 6.17E-03; Fold-change: -9.69E-02; Z-score: -1.70E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C82     Prostate cancer Click to Show/Hide
The Studied Tissue     Prostate
The Specified Disease     Prostate cancer [ICD-11:2C82]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 8.66E-01; Fold-change: -1.19E-01; Z-score: -3.65E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C90     Renal cancer Click to Show/Hide
The Studied Tissue     Kidney
The Specified Disease     Renal cancer [ICD-11:2C90-2C91]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 8.59E-01; Fold-change: -4.51E-02; Z-score: -1.36E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 3.16E-11; Fold-change: -1.98E-01; Z-score: -9.26E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C92     Ureter cancer Click to Show/Hide
The Studied Tissue     Urothelium
The Specified Disease     Ureter cancer [ICD-11:2C92]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.68E-01; Fold-change: -3.39E-02; Z-score: -1.30E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C94     Bladder cancer Click to Show/Hide
The Studied Tissue     Bladder tissue
The Specified Disease     Bladder cancer [ICD-11:2C94]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 6.53E-04; Fold-change: 7.65E-01; Z-score: 2.65E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2D02     Retinal cancer Click to Show/Hide
The Studied Tissue     Uvea
The Specified Disease     Retinoblastoma [ICD-11:2D02.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 3.21E-06; Fold-change: -4.93E-01; Z-score: -6.09E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2D10     Thyroid cancer Click to Show/Hide
The Studied Tissue     Thyroid
The Specified Disease     Thyroid cancer [ICD-11:2D10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 3.46E-07; Fold-change: 2.36E-01; Z-score: 7.25E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 9.64E-02; Fold-change: 3.70E-02; Z-score: 1.52E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2D11     Adrenal cancer Click to Show/Hide
The Studied Tissue     Adrenal cortex
The Specified Disease     Adrenocortical carcinoma [ICD-11:2D11.Z]
The Expression Level of Disease Section Compare with the Other Disease Section     p-value: 5.95E-02; Fold-change: -1.76E-01; Z-score: -1.04E+00
DME expression in the diseased tissue of patients
DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of the other disease section
                  ICD-11: 2D12     Endocrine gland neoplasm Click to Show/Hide
The Studied Tissue     Pituitary tissue
The Specified Disease     Pituitary cancer [ICD-11:2D12]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.79E-02; Fold-change: 2.40E-01; Z-score: 6.54E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Pituitary tissue
The Specified Disease     Pituitary gonadotrope tumour [ICD-11:2D12]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.16E-02; Fold-change: 1.69E-01; Z-score: 7.14E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2D42     Head and neck cancer Click to Show/Hide
The Studied Tissue     Head and neck tissue
The Specified Disease     Head and neck cancer [ICD-11:2D42]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.14E-01; Fold-change: -7.61E-02; Z-score: -3.24E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 03 Blood/blood-forming organ disease Click to Show/Hide
                  ICD-11: 3A51     Sickle cell disorder Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Sickle cell disease [ICD-11:3A51.0-3A51.3]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.28E-01; Fold-change: 2.43E-01; Z-score: 7.45E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 3A70     Aplastic anaemia Click to Show/Hide
The Studied Tissue     Bone marrow
The Specified Disease     Shwachman-Diamond syndrome [ICD-11:3A70.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.13E-01; Fold-change: 4.85E-01; Z-score: 1.58E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 3B63     Thrombocytosis Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Thrombocythemia [ICD-11:3B63]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 6.76E-03; Fold-change: -1.19E-01; Z-score: -1.54E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 3B64     Thrombocytopenia Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Thrombocytopenia [ICD-11:3B64]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.86E-01; Fold-change: 3.72E-01; Z-score: 8.87E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 04 Immune system disease Click to Show/Hide
                  ICD-11: 4A00     Immunodeficiency Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Immunodeficiency [ICD-11:4A00-4A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.53E-01; Fold-change: 3.38E-02; Z-score: 2.92E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 4A40     Lupus erythematosus Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Lupus erythematosus [ICD-11:4A40]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.24E-03; Fold-change: -3.04E-01; Z-score: -6.23E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 4A42     Systemic sclerosis Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Scleroderma [ICD-11:4A42.Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 8.28E-02; Fold-change: 8.85E-02; Z-score: 8.03E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 4A43     Systemic autoimmune disease Click to Show/Hide
The Studied Tissue     Salivary gland tissue
The Specified Disease     Sjogren's syndrome [ICD-11:4A43.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 8.44E-02; Fold-change: -5.80E-01; Z-score: -1.74E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 3.78E-01; Fold-change: 1.62E-01; Z-score: 7.72E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 4A62     Behcet disease Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Behcet's disease [ICD-11:4A62]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.42E-01; Fold-change: 6.96E-02; Z-score: 3.85E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 4B04     Monocyte count disorder Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Autosomal dominant monocytopenia [ICD-11:4B04]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.44E-01; Fold-change: -2.77E-02; Z-score: -1.99E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 05 Endocrine/nutritional/metabolic disease Click to Show/Hide
                  ICD-11: 5A11     Type 2 diabetes mellitus Click to Show/Hide
The Studied Tissue     Omental adipose tissue
The Specified Disease     Obesity related type 2 diabetes [ICD-11:5A11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 8.74E-02; Fold-change: 2.10E-01; Z-score: 1.13E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Liver tissue
The Specified Disease     Type 2 diabetes [ICD-11:5A11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.04E-01; Fold-change: -2.88E-01; Z-score: -5.42E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 5A80     Ovarian dysfunction Click to Show/Hide
The Studied Tissue     Vastus lateralis muscle
The Specified Disease     Polycystic ovary syndrome [ICD-11:5A80.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.22E-01; Fold-change: -3.99E-02; Z-score: -1.53E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 5C51     Inborn carbohydrate metabolism disorder Click to Show/Hide
The Studied Tissue     Biceps muscle
The Specified Disease     Pompe disease [ICD-11:5C51.3]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 8.18E-01; Fold-change: -3.78E-02; Z-score: -2.13E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 5C56     Lysosomal disease Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Batten disease [ICD-11:5C56.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.03E-02; Fold-change: 7.98E-02; Z-score: 1.16E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 5C80     Hyperlipoproteinaemia Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Familial hypercholesterolemia [ICD-11:5C80.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.10E-01; Fold-change: -5.43E-02; Z-score: -3.00E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Whole blood
The Specified Disease     Familial hypercholesterolemia [ICD-11:5C80.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.05E-04; Fold-change: -1.51E-01; Z-score: -8.87E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 06 Mental/behavioural/neurodevelopmental disorder Click to Show/Hide
                  ICD-11: 6A02     Autism spectrum disorder Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Autism [ICD-11:6A02]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.72E-01; Fold-change: 1.22E-01; Z-score: 4.54E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 6A20     Schizophrenia Click to Show/Hide
The Studied Tissue     Prefrontal cortex
The Specified Disease     Schizophrenia [ICD-11:6A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.59E-01; Fold-change: 6.29E-02; Z-score: 3.14E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Superior temporal cortex
The Specified Disease     Schizophrenia [ICD-11:6A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.84E-01; Fold-change: -8.38E-02; Z-score: -8.46E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 6A60     Bipolar disorder Click to Show/Hide
The Studied Tissue     Prefrontal cortex
The Specified Disease     Bipolar disorder [ICD-11:6A60-6A6Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.18E-01; Fold-change: -4.95E-02; Z-score: -3.91E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 6A70     Depressive disorder Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Major depressive disorder [ICD-11:6A70-6A7Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.65E-01; Fold-change: 4.83E-03; Z-score: 2.84E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Hippocampus
The Specified Disease     Major depressive disorder [ICD-11:6A70-6A7Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.64E-01; Fold-change: 2.36E-02; Z-score: 1.75E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 08 Nervous system disease Click to Show/Hide
                  ICD-11: 8A00     Parkinsonism Click to Show/Hide
The Studied Tissue     Substantia nigra tissue
The Specified Disease     Parkinson's disease [ICD-11:8A00.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 8.70E-01; Fold-change: 2.98E-02; Z-score: 1.22E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 8A01     Choreiform disorder Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Huntington's disease [ICD-11:8A01.10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.19E-01; Fold-change: 1.42E-01; Z-score: 7.09E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 8A20     Alzheimer disease Click to Show/Hide
The Studied Tissue     Entorhinal cortex
The Specified Disease     Alzheimer's disease [ICD-11:8A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.30E-01; Fold-change: -1.91E-02; Z-score: -1.41E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 8A2Y     Neurocognitive impairment Click to Show/Hide
The Studied Tissue     White matter tissue
The Specified Disease     HIV-associated neurocognitive impairment [ICD-11:8A2Y-8A2Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.56E-01; Fold-change: -6.08E-02; Z-score: -4.60E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 8A40     Multiple sclerosis Click to Show/Hide
The Studied Tissue     Plasmacytoid dendritic cells
The Specified Disease     Multiple sclerosis [ICD-11:8A40]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.95E-01; Fold-change: -7.47E-02; Z-score: -2.45E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Spinal cord
The Specified Disease     Multiple sclerosis [ICD-11:8A40]
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 9.59E-02; Fold-change: -2.32E-02; Z-score: -1.99E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
                  ICD-11: 8A60     Epilepsy Click to Show/Hide
The Studied Tissue     Peritumoral cortex tissue
The Specified Disease     Epilepsy [ICD-11:8A60-8A6Z]
The Expression Level of Disease Section Compare with the Other Disease Section     p-value: 8.63E-01; Fold-change: 1.56E-01; Z-score: 6.73E-01
DME expression in the diseased tissue of patients
DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of the other disease section
The Studied Tissue     Whole blood
The Specified Disease     Seizure [ICD-11:8A60-8A6Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.32E-01; Fold-change: 7.56E-02; Z-score: 4.21E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 8B01     Subarachnoid haemorrhage Click to Show/Hide
The Studied Tissue     Intracranial artery
The Specified Disease     Intracranial aneurysm [ICD-11:8B01.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.54E-01; Fold-change: 8.93E-02; Z-score: 4.64E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 8B11     Cerebral ischaemic stroke Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Cardioembolic stroke [ICD-11:8B11.20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.10E-01; Fold-change: -4.38E-02; Z-score: -3.62E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Peripheral blood
The Specified Disease     Ischemic stroke [ICD-11:8B11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.41E-01; Fold-change: 6.24E-02; Z-score: 6.02E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 8B60     Motor neuron disease Click to Show/Hide
The Studied Tissue     Skin
The Specified Disease     Lateral sclerosis [ICD-11:8B60.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 3.40E-01; Fold-change: 1.04E-01; Z-score: 7.11E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Cervical spinal cord
The Specified Disease     Lateral sclerosis [ICD-11:8B60.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.43E-01; Fold-change: 2.19E-03; Z-score: 1.72E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 8C70     Muscular dystrophy Click to Show/Hide
The Studied Tissue     Muscle tissue
The Specified Disease     Myopathy [ICD-11:8C70.6]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.32E-03; Fold-change: -2.71E-01; Z-score: -1.58E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 8C75     Distal myopathy Click to Show/Hide
The Studied Tissue     Muscle tissue
The Specified Disease     Tibial muscular dystrophy [ICD-11:8C75]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.51E-09; Fold-change: -6.44E-01; Z-score: -3.30E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 09 Visual system disease Click to Show/Hide
                  ICD-11: 9A96     Anterior uveitis Click to Show/Hide
The Studied Tissue     Peripheral monocyte
The Specified Disease     Autoimmune uveitis [ICD-11:9A96]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.04E-03; Fold-change: -3.73E-01; Z-score: -1.91E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 11 Circulatory system disease Click to Show/Hide
                  ICD-11: BA41     Myocardial infarction Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Myocardial infarction [ICD-11:BA41-BA50]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.19E-02; Fold-change: 3.12E-01; Z-score: 8.06E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: BA80     Coronary artery disease Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Coronary artery disease [ICD-11:BA80-BA8Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 8.21E-01; Fold-change: -3.72E-02; Z-score: -1.96E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: BB70     Aortic valve stenosis Click to Show/Hide
The Studied Tissue     Calcified aortic valve
The Specified Disease     Aortic stenosis [ICD-11:BB70]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.67E-01; Fold-change: 1.35E-01; Z-score: 2.39E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 12 Respiratory system disease Click to Show/Hide
                  ICD-11: 7A40     Central sleep apnoea Click to Show/Hide
The Studied Tissue     Hyperplastic tonsil
The Specified Disease     Apnea [ICD-11:7A40]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.31E-01; Fold-change: -1.20E-01; Z-score: -6.20E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: CA08     Vasomotor or allergic rhinitis Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Olive pollen allergy [ICD-11:CA08.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.85E-01; Fold-change: -6.08E-02; Z-score: -2.34E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: CA0A     Chronic rhinosinusitis Click to Show/Hide
The Studied Tissue     Sinus mucosa tissue
The Specified Disease     Chronic rhinosinusitis [ICD-11:CA0A]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.47E-01; Fold-change: -1.46E-01; Z-score: -1.13E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: CA22     Chronic obstructive pulmonary disease Click to Show/Hide
The Studied Tissue     Lung tissue
The Specified Disease     Chronic obstructive pulmonary disease [ICD-11:CA22]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 8.01E-02; Fold-change: 6.73E-02; Z-score: 3.36E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Small airway epithelium
The Specified Disease     Chronic obstructive pulmonary disease [ICD-11:CA22]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.91E-04; Fold-change: 1.41E-01; Z-score: 6.14E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: CA23     Asthma Click to Show/Hide
The Studied Tissue     Nasal and bronchial airway
The Specified Disease     Asthma [ICD-11:CA23]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.21E-04; Fold-change: -2.33E-01; Z-score: -5.09E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: CB03     Idiopathic interstitial pneumonitis Click to Show/Hide
The Studied Tissue     Lung tissue
The Specified Disease     Idiopathic pulmonary fibrosis [ICD-11:CB03.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.89E-01; Fold-change: -1.95E-01; Z-score: -9.15E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 13 Digestive system disease Click to Show/Hide
                  ICD-11: DA0C     Periodontal disease Click to Show/Hide
The Studied Tissue     Gingival tissue
The Specified Disease     Periodontal disease [ICD-11:DA0C]
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 2.35E-02; Fold-change: 7.37E-02; Z-score: 3.65E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
                  ICD-11: DA42     Gastritis Click to Show/Hide
The Studied Tissue     Gastric antrum tissue
The Specified Disease     Eosinophilic gastritis [ICD-11:DA42.2]
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 5.90E-02; Fold-change: 1.81E-01; Z-score: 1.47E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
                  ICD-11: DB92     Non-alcoholic fatty liver disease Click to Show/Hide
The Studied Tissue     Liver tissue
The Specified Disease     Non-alcoholic fatty liver disease [ICD-11:DB92]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.95E-01; Fold-change: -1.11E-01; Z-score: -5.80E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: DB99     Hepatic failure Click to Show/Hide
The Studied Tissue     Liver tissue
The Specified Disease     Liver failure [ICD-11:DB99.7-DB99.8]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.60E-02; Fold-change: -2.52E-01; Z-score: -1.10E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: DD71     Ulcerative colitis Click to Show/Hide
The Studied Tissue     Colon mucosal tissue
The Specified Disease     Ulcerative colitis [ICD-11:DD71]
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 2.70E-01; Fold-change: 1.35E-01; Z-score: 4.45E-01
DME expression in the diseased tissue of patients
DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of the other disease section
                  ICD-11: DD91     Irritable bowel syndrome Click to Show/Hide
The Studied Tissue     Rectal colon tissue
The Specified Disease     Irritable bowel syndrome [ICD-11:DD91.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 8.20E-01; Fold-change: -1.63E-03; Z-score: -1.13E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 14 Skin disease Click to Show/Hide
                  ICD-11: EA80     Atopic eczema Click to Show/Hide
The Studied Tissue     Skin
The Specified Disease     Atopic dermatitis [ICD-11:EA80]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 3.35E-02; Fold-change: 2.21E-02; Z-score: 1.60E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: EA90     Psoriasis Click to Show/Hide
The Studied Tissue     Skin
The Specified Disease     Psoriasis [ICD-11:EA90]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.74E-01; Fold-change: -3.86E-02; Z-score: -1.04E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 9.54E-11; Fold-change: 3.09E-01; Z-score: 1.21E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: ED63     Acquired hypomelanotic disorder Click to Show/Hide
The Studied Tissue     Skin
The Specified Disease     Vitiligo [ICD-11:ED63.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.77E-01; Fold-change: -2.23E-02; Z-score: -1.96E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: ED70     Alopecia or hair loss Click to Show/Hide
The Studied Tissue     Skin from scalp
The Specified Disease     Alopecia [ICD-11:ED70]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.07E-01; Fold-change: -1.74E-02; Z-score: -7.66E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: EK0Z     Contact dermatitis Click to Show/Hide
The Studied Tissue     Skin
The Specified Disease     Sensitive skin [ICD-11:EK0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.28E-02; Fold-change: 7.52E-02; Z-score: 6.09E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 15 Musculoskeletal system/connective tissue disease Click to Show/Hide
                  ICD-11: FA00     Osteoarthritis Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Arthropathy [ICD-11:FA00-FA5Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.39E-02; Fold-change: 3.35E-02; Z-score: 3.25E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Synovial tissue
The Specified Disease     Osteoarthritis [ICD-11:FA00-FA0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.41E-01; Fold-change: -1.97E-01; Z-score: -7.83E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: FA20     Rheumatoid arthritis Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Childhood onset rheumatic disease [ICD-11:FA20.Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.46E-01; Fold-change: 3.70E-02; Z-score: 1.18E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Synovial tissue
The Specified Disease     Rheumatoid arthritis [ICD-11:FA20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.61E-03; Fold-change: -6.79E-01; Z-score: -2.18E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: FA24     Juvenile idiopathic arthritis Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Juvenile idiopathic arthritis [ICD-11:FA24]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 6.87E-01; Fold-change: -3.81E-02; Z-score: -1.61E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: FA92     Inflammatory spondyloarthritis Click to Show/Hide
The Studied Tissue     Pheripheral blood
The Specified Disease     Ankylosing spondylitis [ICD-11:FA92.0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.53E-01; Fold-change: 1.21E-03; Z-score: 1.45E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: FB83     Low bone mass disorder Click to Show/Hide
The Studied Tissue     Bone marrow
The Specified Disease     Osteoporosis [ICD-11:FB83.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.53E-04; Fold-change: 4.13E-01; Z-score: 3.30E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 16 Genitourinary system disease Click to Show/Hide
                  ICD-11: GA10     Endometriosis Click to Show/Hide
The Studied Tissue     Endometrium tissue
The Specified Disease     Endometriosis [ICD-11:GA10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 3.63E-01; Fold-change: 8.24E-02; Z-score: 3.98E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: GC00     Cystitis Click to Show/Hide
The Studied Tissue     Bladder tissue
The Specified Disease     Interstitial cystitis [ICD-11:GC00.3]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.22E-01; Fold-change: 6.96E-02; Z-score: 1.92E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 19 Condition originating in perinatal period Click to Show/Hide
                  ICD-11: KA21     Short gestation disorder Click to Show/Hide
The Studied Tissue     Myometrium
The Specified Disease     Preterm birth [ICD-11:KA21.4Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.79E-01; Fold-change: -1.18E-01; Z-score: -8.68E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 20 Developmental anomaly Click to Show/Hide
                  ICD-11: LD2C     Overgrowth syndrome Click to Show/Hide
The Studied Tissue     Adipose tissue
The Specified Disease     Simpson golabi behmel syndrome [ICD-11:LD2C]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.86E-01; Fold-change: -5.48E-02; Z-score: -4.55E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: LD2D     Phakomatoses/hamartoneoplastic syndrome Click to Show/Hide
The Studied Tissue     Perituberal tissue
The Specified Disease     Tuberous sclerosis complex [ICD-11:LD2D.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.79E-01; Fold-change: 8.11E-02; Z-score: 1.23E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
References
1 Pharmacokinetics of bambuterol in subjects homozygous for the atypical gene for plasma cholinesterase
2 Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016 Jul;71(7):1755-8.
3 In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. Biochem Pharmacol. 2017 Jan 1;123:85-96.
4 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
5 Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans
6 Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
7 Identification of Novel Pathways in Idelalisib Metabolism and Bioactivation
8 DrugBank(Pharmacology-Metabolism)Estrone
9 Metabolomics of Methylphenidate and Ethylphenidate: Implications in Pharmacological and Toxicological Effects
10 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
11 Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol. 1991 Jul;40(1):63-8.
12 PubChem:Pimavanserin
13 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
14 Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001 Jan;41(1):85-91.
15 CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97.
16 Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol. 1992 Dec 1;44(11):2089-98.
17 Characterization of In Vitro and In Vivo Metabolism of Antazoline Using Liquid Chromatography-Tandem Mass Spectrometry
18 Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383-92.
19 Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97.
20 Revisiting the metabolism of ketoconazole using accurate mass Drug Metab Lett. 2009 Aug;3(3):191-8. doi: 10.2174/187231209789352085.
21 Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica. 2014 Apr;44(4):309-319.
22 Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
23 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
24 Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
25 Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.
26 Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
27 Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
28 Multiple cytochrome P450 enzymes responsible for the oxidative metabolism of the substituted (S)-3-phenylpiperidine, (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, in human liver microsomes. Drug Metab Dispos. 2002 Dec;30(12):1372-7.
29 Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos. 2000 Aug;28(8):959-65.
30 Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
31 Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
32 The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther. 1996 Jun;277(3):1659-64.
33 Priapism induced by boceprevir-CYP3A4 inhibition and alpha-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan;58(1):e35-8.
34 CYP2C76-mediated species difference in drug metabolism: a comparison of pitavastatin metabolism between monkeys and humans
35 Effect of health foods on cytochrome P450-mediated drug metabolism. J Pharm Health Care Sci. 2017 May 10;3:14.
36 A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42.
37 Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):893-903.
38 Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. Fundam Clin Pharmacol. 2007 Aug;21(4):437-43.
39 Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5.
40 Pharmacogenomics knowledge for personalized medicine Clin Pharmacol Ther. 2012 Oct;92(4):414-7. doi: 10.1038/clpt.2012.96.
41 Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer. Pharmacogenomics. 2017 May;18(7):601-605.
42 Erythromycin interaction with risperidone or clomipramine in an adolescent. J Child Adolesc Psychopharmacol. 1996 Summer;6(2):133-8.
43 Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91.
44 Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
45 Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine. J Clin Pharmacol. 1992 Feb;32(2):176-83.
46 Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta-3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40.
47 Metabolism and disposition of prescription opioids: a review. Forensic Sci Rev. 2015 Jul;27(2):115-45.
48 Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87.
49 Ranolazine: a contemporary review. J Am Heart Assoc. 2016 Mar 15;5(3):e003196.
50 In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
51 Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites
52 Effect of the CYP2D6*10 allele on the pharmacokinetics of clomiphene and its active metabolites
53 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
54 Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54.
55 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
56 The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad Emerg Med. 2014 Aug;21(8):879-85.
57 Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci. 1998 Oct;87(10):1184-9.
58 Biocatalytic synthesis and structure elucidation of cyclized metabolites of the deacetylase inhibitor panobinostat (LBH589) Drug Metab Dispos. 2012 May;40(5):1041-50. doi: 10.1124/dmd.111.043620.
59 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
60 Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir
61 Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica. 1998 Oct;28(10):909-22.
62 Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele
63 Brexpiprazole: first global approval. Drugs. 2015 Sep;75(14):1687-97.
64 Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol. 1998 Jun;18(3):198-207.
65 FDA Label of Deutetrabenazine. The 2020 official website of the U.S. Food and Drug Administration.
66 Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723.
67 Doxepin inhibits CYP2D6 activity in vivo. Pol J Pharmacol. 2004 Jul-Aug;56(4):491-4.
68 Eliglustat: first global approval. Drugs. 2014 Oct;74(15):1829-36.
69 FDA Approved Drug Products: Perforomist? inhalation solution
70 Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
71 Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects
72 DrugBank(Pharmacology-Metabolism):Lasofoxifene
73 Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
74 Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet. 2004;43(4):267-78.
75 Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999 Dec;27(12):1488-95.
76 Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8.
77 Population pharmacokinetics of pomalidomide. J Clin Pharmacol. 2015 May;55(5):563-72.
78 Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes. J Clin Psychopharmacol. 2000 Aug;20(4):428-34.
79 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
80 Evaluating the role of drug metabolism and reactive intermediates in trazodone-induced cytotoxicity toward freshly-isolated rat hepatocytes. Drug Res (Stuttg). 2016 Nov;66(11):592-596.
81 The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Ther Adv Respir Dis. 2013 Dec;7(6):311-9.
82 Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
83 Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin Ther. 2000 May;22(5):549-72.
84 The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur J Drug Metab Pharmacokinet. 1998 Jul-Sep;23(3):429-36.
85 Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26.
86 Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther. 2007 Jan;320(1):344-53.
87 DrugBank(Pharmacology-Metabolism):Betrixaban
88 Metabolite Profiling and Reaction Phenotyping for the in Vitro Assessment of the Bioactivation of Bromfenac ? Chem Res Toxicol. 2020 Jan 21;33(1):249-257. doi: 10.1021/acs.chemrestox.9b00268.
89 Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7.
90 Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs. Arzneimittelforschung. 2003;53(1):26-33.
91 Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303-11.
92 The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50.
93 Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol. 1999 Apr;47(4):450-3.
94 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
95 Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease. Eur J Clin Pharmacol. 2016 Jun;72(6):711-7.
96 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
97 Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats. Eur J Pharm Sci. 2018 Jan 1;111:13-19.
98 Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state Drug Metab Dispos. 2010 May;38(5):808-16. doi: 10.1124/dmd.109.030833.
99 (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91.
100 Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet. 2001;40(4):263-81.
101 QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother. 2005 Mar;39(3):543-6.
102 Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96.
103 Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
104 Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers Drug Metab Dispos. 2019 Feb;47(2):104-113. doi: 10.1124/dmd.118.080549.
105 LABEL:PREVYMIS- letermovir tablet, film coated PREVYMIS- letermovir injection, solution
106 Influence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences. PLoS One. 2014 Nov 4;9(11):e90453.
107 Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug. Neuropharmacology. 2014 Dec;87:41-50.
108 The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine. Br J Clin Pharmacol. 2018 Dec;84(12):2704-2715.
109 Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54.
110 Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl). 1999 Jul;145(1):113-22.
111 [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring]. Fortschr Neurol Psychiatr. 2001 Nov;69(11):510-7.
112 Binding of quinidine radically increases the stability and decreases the flexibility of the cytochrome P450 2D6 active site. J Inorg Biochem. 2012 May;110:46-50.
113 A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respir Res. 2017 Nov 2;18(1):182.
114 Evaluation of absorption, distribution, metabolism, and excretion of [(14)C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors Invest New Drugs. 2020 Jun;38(3):765-775. doi: 10.1007/s10637-019-00815-2.
115 Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs. 2004;4(4):247-55.
116 Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75.
117 In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76.
118 Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm Drug Dispos. 2002 Dec;23(9):361-7.
119 Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf. 2003;26(6):421-38.
120 Addition of amoxapine improves positive and negative symptoms in a patient with schizophrenia Ther Adv Psychopharmacol. 2013 Dec;3(6):340-2. doi: 10.1177/2045125313499363.
121 Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Jul;27(7):792-7.
122 Effect of nonspecific binding to microsomes and metabolic elimination of buprenorphine on the inhibition of cytochrome P4502D6. Biol Pharm Bull. 2005 Feb;28(2):212-6.
123 Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69.
124 CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6.
125 Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
126 Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos. 2007 Jan;35(1):72-8.
127 Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy. Cancer Manag Res. 2012;4:67-73.
128 Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes Xenobiotica. 2003 Mar;33(3):265-76. doi: 10.1080/0049825021000061606.
129 CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Dispos. 2011 Feb;39(2):191-8.
130 In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011 Oct;32(7):398-407.
131 Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics. 2001 Aug;11(6):477-87.
132 A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64.
133 A dual system platform for drug metabolism: Nalbuphine as a model compound
134 Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54.
135 Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015 Aug;98(2):127-34.
136 Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011 Mar 5;71(4):443-54.
137 The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients. J Clin Psychopharmacol. 2015 Jun;35(3):228-36.
138 Novel pathways of ponatinib disposition catalyzed by CYP1A1 involving generation of potentially toxic metabolites. J Pharmacol Exp Ther. 2017 Oct;363(1):12-19.
139 ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib
140 DrugBank(Pharmacology-Metabolism):Pralsetinib
141 Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol. 2004 Apr;57(4):464-72.
142 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
143 A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol. 2004 Sep;28(6):443-8.
144 Reversible coma caused by risperidone-ritonavir interaction. Clin Neuropharmacol. 2002 Sep-Oct;25(5):251-3.
145 Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
146 Metabolism of sumatriptan revisited
147 Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes
148 Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist J Clin Pharmacol. 2015 Sep;55(9):1004-11. doi: 10.1002/jcph.507.
149 Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol. 1995 Jul 17;50(2):205-11.
150 Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003 May;59(1):45-50.
151 Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
152 Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells
153 The associations between CYP2D6 metabolizer status and pharmacokinetics and clinical outcomes of venlafaxine: a systematic review and meta-analysis. Pharmacopsychiatry. 2019 Sep;52(5):222-231.
154 Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.
155 Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
156 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
157 Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999 Jul;29(7):719-32.
158 Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.
159 More methemoglobin is produced by benzocaine treatment than lidocaine treatment in human in vitro systems
160 Binimetinib Is a Potent Reversible and Time-Dependent Inhibitor of Cytochrome P450 1A2 Chem Res Toxicol. 2021 Apr 19;34(4):1169-1174. doi: 10.1021/acs.chemrestox.1c00036.
161 The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol. 2002 May;53(5):519-25.
162 Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur J Drug Metab Pharmacokinet. 2005 Oct-Dec;30(4):275-86.
163 Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
164 A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement Drug Metab Dispos. 2015 Apr;43(4):523-33. doi: 10.1124/dmd.114.062620.
165 Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9.
166 Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet. 2005;44(10):1067-81.
167 Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis. Acta Pharmacol Sin. 2016 Nov;37(11):1499-1508.
168 Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan
169 N-demethylation of levo-alpha-acetylmethadol by human placental aromatase. Biochem Pharmacol. 2004 Mar 1;67(5):885-92.
170 The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review Curr Neuropharmacol. 2016;14(2):191-9. doi: 10.2174/1570159x14666151117122458.
171 Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004 Oct;60(8):575-81.
172 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
173 Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol. 2002 Mar;90(3):144-9.
174 Meclizine metabolism and pharmacokinetics: formulation on its absorption. J Clin Pharmacol. 2012 Sep;52(9):1343-9.
175 Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
176 Lack of interaction between amiodarone and mexiletine in cardiac arrhythmia patients. J Clin Pharmacol. 2002 Mar;42(3):342-6.
177 Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers. Eur J Clin Pharmacol. 2003 Sep;59(5-6):395-9.
178 Akathisia with combined use of midodrine and promethazine. JAMA. 2006 May 3;295(17):2000-1. Letter
179 Ema.europa:Pitolisant
180 Involvement of CYP2D6 activity in the N-oxidation of procainamide in man. Pharmacogenetics. 1999 Dec;9(6):683-96.
181 Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol. 2000 Oct;84(2):213-20.
182 PubChem:Tapinarof
183 Cardiac safety of ophthalmic timolol. Expert Opin Drug Saf. 2016 Nov;15(11):1549-1561.
184 Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics. Drug Metab Dispos. 2010 Sep;38(9):1456-63.
185 Metabolism and pharmacokinetics of the combination Zidovudine plus Lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis
186 An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015 Dec;42(12):1225-38.
187 A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
188 Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450
189 Lithium Intoxication in the Elderly: A Possible Interaction between Azilsartan, Fluvoxamine, and Lithium
190 Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):193-206.
191 Involvement of CYP2D1 in the metabolism of carteolol by male rat liver microsomes. Xenobiotica. 1997 Nov;27(11):1121-9.
192 Celecoxib is a substrate of CYP2D6: impact on celecoxib metabolism in individuals with CYP2C9*3 variants. Drug Metab Pharmacokinet. 2018 Oct;33(5):219-227.
193 Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
194 Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
195 Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9.
196 CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression. Psychiatry Investig. 2013 Sep;10(3):286-93.
197 Flecainide: current status and perspectives in arrhythmia management. World J Cardiol. 2015 Feb 26;7(2):76-85.
198 LABEL:DDYI- flibanserin tablet, film coated
199 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants
200 Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J Pharmacol Exp Ther. 1997 Mar;280(3):1374-82.
201 An updated review of iclaprim: a potent and rapidly bactericidal antibiotic for the treatment of skin and skin structure infections and nosocomial pneumonia caused by gram-positive including multidrug-resistant bacteria. Open Forum Infect Dis. 2018 Jan 6;5(2):ofy003.
202 In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab Dispos. 2001 Sep;29(9):1173-5.
203 Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet. 2004 Apr;19(2):83-95.
204 Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull. 2005 May;28(5):882-5.
205 Molecular basis of polymorphic drug metabolism. J Mol Med (Berl). 1995 Nov;73(11):539-53.
206 Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6. Eur J Clin Pharmacol. 1995;48(1):35-8.
207 Interpreting serum risperidone concentrations. Pharmacotherapy. 2005 Feb;25(2):299-302.
208 DrugBank(Pharmacology-Metabolism):Phenmetrazine
209 Physiologically Based Pharmacokinetic Modeling of Transdermal Selegiline and Its Metabolites for the Evaluation of Disposition Differences between Healthy and Special Populations
210 Inter- and intraindividual pharmacokinetic variations in the treatment of Parkinson's disease. Rinsho Shinkeigaku. 2005 Nov;45(11):895-8.
211 Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004 Jan-Feb;59(1):5-12.
212 Role of tetrabenazine for Huntington's disease-associated chorea. Ann Pharmacother. 2010 Jun;44(6):1080-9.
213 Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3(4):247-68.
214 Tiotropium rromide/olodaterol (Stiolto Respimat): once-daily combination therapy for the maintenance of COPD. P T. 2016 Feb;41(2):97-102.
215 FDA Label of Egaten. The 2020 official website of the U.S. Food and Drug Administration.
216 Galactorrhea during treatment with trimipramine. A case report. Pharmacopsychiatry. 2005 Nov;38(6):326-7.
217 Pharmacokinetics, toxicological and clinical aspects of ulipristal acetate: insights into the mechanisms implicated in the hepatic toxicity Drug Metab Rev. 2021 Aug;53(3):375-383. doi: 10.1080/03602532.2021.1917599.
218 Pharmacokinetics, metabolite profiling, safety, and tolerability of inhalation aerosol of 101BHG-D01, a novel, long-acting and selective muscarinic receptor antagonist, in healthy Chinese subjects
219 DrugBank(Pharmacology-Metabolism):Umeclidinium
220 Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert Rev Neurother. 2018 Apr;18(4):323-332.
221 Mechanism of cytochrome P4503A4- and 2D6-catalyzed dehydrogenation of ezlopitant as probed with isotope effects using five deuterated analogs. Drug Metab Dispos. 2001 Dec;29(12):1599-607.
222 Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22.
223 Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol. 1998 Mar;45(3):315-7.
224 Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters Curr Drug Metab. 2020;21(14):1127-1135. doi: 10.2174/1389200221999201208211537.
225 Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Nov;27(11):1274-80.
226 Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
227 Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 2018 May;48(5):459-466.
228 Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996;51(1):73-8.
229 Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018 Mar;30(2):125-133.
230 Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92.
231 Pharmacogenetic Gene-Drug Associations in Pediatric Burn and Surgery Patients
232 Engineering of cytochrome P450 3A4 for enhanced peroxide-mediated substrate oxidation using directed evolution and site-directed mutagenesis. Drug Metab Dispos. 2006 Dec;34(12):1958-65.
233 Cross-species comparisons of the pharmacokinetics of ibudilast
234 In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
235 Drugs and steatohepatitis. Semin Liver Dis. 2002;22(2):185-94.
236 Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57.
237 A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans. Clin Transl Sci. 2017 Mar;10(2):93-101.
238 Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates
239 Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit. 2004 Apr;26(2):127-31.
240 Crystal structure of human cytochrome P450 2D6 with prinomastat bound
241 Xenobiotic-metabolizing cytochromes p450 in human white adipose tissue: expression and induction. Drug Metab Dispos. 2010 Apr;38(4):679-86.
242 DrugBank(Pharmacology-Metabolism):Ripretinib
243 Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther. 2005 Nov;78(5):520-8.
244 SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels? Drug Test Anal. 2015 Feb;7(2):109-13. doi: 10.1002/dta.1645.
245 Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. Drug Des Devel Ther. 2016 Jul 26;10:2387-99.
246 In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6
247 Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
248 Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity. Drug Metab Pharmacokinet. 2015 Aug;30(4):257-62.
249 Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol. 2004 Sep;60(7):473-80.
250 DrugBank(Pharmacology-Metabolism):Elagolix sodium
251 Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
252 Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil
253 Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I-III clinical trials. Clin Pharmacokinet. 2019 Aug;58(8):1045-1058.
254 PubChem:Upadacitinib
255 CYP2D plays a major role in berberine metabolism in liver of mice and humans
256 Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):4-22.
257 Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6. Bioorg Med Chem. 2003 Dec 1;11(24):5545-54.
258 Dapoxetine: a new option in the medical management of premature ejaculation. Ther Adv Urol. 2012 Oct;4(5):233-51.
259 No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine
260 Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A. Drug Metab Dispos. 2000 Sep;28(9):1128-34.
261 Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy. Psychiatr Pol. 2004 Nov-Dec;38(6):1093-104.
262 In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
263 Assessments of CYP?inhibition?based drug-drug interaction between vonoprazan and poziotinib in?vitro and in?vivo
264 Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
265 Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. Br J Clin Pharmacol. 2001 Feb;51(2):133-42.
266 Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2. Pharmacogenetics. 1998 Oct;8(5):423-32.
267 The role of active metabolites in dihydrocodeine effects. Int J Clin Pharmacol Ther. 2003 Mar;41(3):95-106.
268 Pharmacokinetic evaluation of idebenone. Expert Opin Drug Metab Toxicol. 2010 Nov;6(11):1437-44.
269 Differences in the In Vivo and In Vitro Metabolism of Imrecoxib in Humans: Formation of the Rate-Limiting Aldehyde Intermediate Drug Metab Dispos. 2018 Sep;46(9):1320-1328. doi: 10.1124/dmd.118.081182.
270 Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants. doi: 10.1002/9781118105955.ch13
271 Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J Pharm Sci. 1998 Dec;87(12):1502-7.
272 Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol. 2016 Feb;72(2):175-84.
273 Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
274 Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol. 1997;52(1):41-7.
275 Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet. 2000 Feb;38(2):111-80.
276 Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl). 2000 Sep;151(4):312-20.
277 DMW/ISSX 2000 Meeting. The Drug Metabolism Workshop/International Society for the Study of Xenobiotics. St. Andrews, Scotland, June 11-16, 2000. Abstracts. Drug Metab Rev. 2000;32 Suppl 1:1-136.
278 CYP2D6 is primarily responsible for the metabolism of clomiphene. Drug Metab Pharmacokinet. 2008;23(2):101-5.
279 VMAT2 Inhibitors in Neuropsychiatric Disorders
280 DrugBank(Pharmacology-Metabolism)Lofexidine
281 Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride Drug Metab Dispos. 2012 Sep;40(9):1723-35. doi: 10.1124/dmd.112.045120.
282 FDA LABEL:Milnacipran
283 Serotonin and Norepinephrine Reuptake Inhibitors
284 Management of postoperative nausea and vomiting: focus on palonosetron
285 Phase I pharmacokinetic study of the novel antitumor agent SR233377. Clin Cancer Res. 2000 Aug;6(8):3088-94.
286 Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype. Psychopharmacology (Berl). 2011 May;215(2):321-32.
287 Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. Br J Clin Pharmacol. 1996 Dec;42(6):707-11.
288 Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain. Endocrinology. 2004 Feb;145(2):699-705.
289 Relationship of cytochrome P450 pharmacogenetics to the effects of yohimbine on gastrointestinal transit and catecholamines in healthy subjects. Neurogastroenterol Motil. 2008 Aug;20(8):891-9.
290 Plasma protein binding, pharmacokinetics, tissue distribution and CYP450 biotransformation studies of fidarestat by ultra high performance liquid chromatography-high resolution mass spectrometry
291 Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics
292 Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives. Eur J Pharmacol. 1995 Oct 6;293(3):183-90.
293 Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
294 Asunaprevir: a review of preclinical and clinical pharmacokinetics and drug-drug interactions. Clin Pharmacokinet. 2015 Dec;54(12):1205-22.
295 Pharmacokinetics, Disposition, and Biotransformation of [(14)C]Omecamtiv Mecarbil in Healthy Male Subjects after a Single Intravenous or Oral Dose
296 Metabolism and disposition of hepatitis C polymerase inhibitor dasabuvir in humans. Drug Metab Dispos. 2016 Aug;44(8):1139-47.
297 DrugBank(Pharmacology-Metabolism):Chlorpromazine
298 In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human. Drug Metab Dispos. 2007 Dec;35(12):2232-41.
299 Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87.
300 The metabolic profile of azimilide in man: in vivo and in vitro evaluations. J Pharm Sci. 2005 Sep;94(9):2084-95.
301 Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther. 1995 Jun;57(6):670-7.
302 The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine
303 Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans
304 The potent mechanism-based inactivation of CYP2D6 and CYP3A4 with fusidic acid in in vivo bioaccumulation. Xenobiotica. 2018 Oct;48(10):999-1005.
305 DrugBank(Pharmacology-Metabolism):BMS-986165
306 Idalopirdine as a treatment for Alzheimer's disease. Expert Opin Investig Drugs. 2015;24(7):981-7.
307 Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans. Drug Metab Dispos. 2010 Apr;38(4):554-65.
308 Effect of netupitant, a highly selective NK?receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer. 2013 Oct;21(10):2879-87.
309 CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):128-38.
310 A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors
311 DrugBank(Pharmacology-Metabolism)BRN-1907611
312 Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone. Xenobiotica. 2009 Jan;39(1):1-10.
313 In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions
314 Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs
315 Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults
316 Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J Clin Pharmacol. 2009 Jan;49(1):17-29.
317 Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development. J Clin Pharmacol. 2003 Sep;43(9):1008-14.
318 DrugBank(Pharmacology-Metabolism):Ganaxolone
319 DrugBank(Pharmacology-Metabolism):MRTX849
320 Nefazodone pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry. 2000 Aug;39(8):1008-16.
321 In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT(1A) Receptor Agonist for the Treatment of Schizophrenia
322 In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos. 2000 Apr;28(4):392-7.
323 DrugBank(Pharmacology-Metabolism):Ag-221
324 Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers
325 Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
326 Interpretation of opiate urine drug screens.
327 Oxidative Deamination of Emixustat by Human Vascular Adhesion Protein-1/Semicarbazide-Sensitive Amine Oxidase
328 DrugBank(Pharmacology-Metabolism):Verapamil
329 Novel binding mode of the acidic CYP2D6 substrates pactimibe and its metabolite R-125528. Drug Metab Dispos. 2008 Sep;36(9):1938-43.
330 Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies
331 Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
332 Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human
333 CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib
334 Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man
335 Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite
336 Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs
337 Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution. Proteins. 2005 May 1;59(2):339-46.
338 Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004 Apr;26(2):137-44.
339 Cytochrome P450 enzymes involved in the metabolic pathway of the histamine 2 (H2)-receptor antagonist roxatidine acetate by human liver microsomes. Arzneimittelforschung. 2001;51(8):651-8.
340 Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol. 2006 Mar;147(5):476-85.
341 Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers. Species comparison and allometric scaling
342 Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2 Inhibitor PT2385 In Vivo and In Vitro
343 Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients
344 Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)
345 Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos. 2000 Dec;28(12):1397-400.
346 Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers
347 In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006 Apr;34(4):667-82.
348 Effect of deuteration on metabolism and clearance of Nerispirdine (HP184) and AVE5638
349 Metabolism of the newest antidepressants: comparisons with related predecessors. IDrugs. 2004 Feb;7(2):143-50.
350 Cytochrome P450 Mediated Bioactivation of Saracatinib
351 Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003 May;31(5):631-6.
352 In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptor. Drug Metab Pharmacokinet. 2007 Oct;22(5):336-49.
353 Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
354 Evaluation of the inhibitory and induction potential of YM758, a novel If channel inhibitor, for human P450-mediated metabolism
355 Pharmacokinetics, tissue distribution and identification of putative metabolites of JI-101 - a novel triple kinase inhibitor in rats
356 Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors. Xenobiotica. 2014 Sep;44(9):827-41.
357 Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics. Antimicrob Agents Chemother. 2015 Jul;59(7):3864-9.
358 Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors
359 Comparative pharmacokinetic profile of cimicoxib in dogs and cats after IV administration
360 The pharmacogenetics of the new-generation antipsychotics - A scoping review focused on patients with severe psychiatric disorders
361 In vitro metabolism, pharmacokinetics and drug interaction potentials of emvododstat, a DHODH inhibitor
362 Evaluation of the drug-drug interaction potential for trazpiroben (TAK-906), a D(2)/D(3) receptor antagonist for gastroparesis, towards cytochrome P450s and transporters
363 DrugBank(Pharmacology-Metabolism):KD025
364 Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
365 Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation. Klin Wochenschr. 1985 Nov 15;63(22):1180-6.
366 First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol. 2014 Mar;54(3):351-7.
367 Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804.
368 Metabolism and pharmacokinetics of allitinib in cancer patients: the roles of cytochrome P450s and epoxide hydrolase in its biotransformation
369 Pharmacokinetics and Metabolism of Naringin and Active Metabolite Naringenin in Rats, Dogs, Humans, and the Differences Between Species
370 Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
371 Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004 Aug;26(4):361-5.
372 In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes
373 In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent
374 Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours
375 Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans
376 Development of a liquid chromatography/tandem-mass spectrometry assay for the simultaneous determination of teneligliptin and its active metabolite teneligliptin sulfoxide in human plasma
377 Nonlinear mixed effects model analysis of the pharmacokinetics of routinely administered bepridil in Japanese patients with arrhythmias. Biol Pharm Bull. 2006 Mar;29(3):517-21.
378 Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009 Jun;72(2):471-7.
379 Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48.
380 Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug
381 ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36.
382 Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease
383 In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans
384 An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant
385 A pharmacokinetic interaction study of avitriptan and propranolol
386 In vitro metabolism of 7 neuronal nicotinic receptor agonist AZD0328 and enzyme identification for its N-oxide metabolite
387 Main metabolic pathways of TAK-802, a novel drug candidate for voiding dysfunction, in humans: the involvement of carbonyl reduction by 11-hydroxysteroid dehydrogenase 1
388 Identification of cytochrome P450 isoform involved in the metabolism of YM992, a novel selective serotonin re-uptake inhibitor, in human liver microsomes
389 Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (Clevudine) and 2',3'-didehydro-2',3'-dideoxythymidine in cells. Antimicrob Agents Chemother. 2005 May;49(5):2044-9. doi: 10.1128/AAC.49.5.2044-2049.2005.
390 Evaluation of the effects of AZD3480 on cardiac repolarization: a thorough QT/QTc study using moxifloxacin as a positive control
391 Species-dependent metabolism of a novel selective 7 neuronal acetylcholine receptor agonist ABT-107
392 In vitro interactions between a potential muscle relaxant E2101 and human cytochromes P450
393 In-vitro metabolism of YM17E, an inhibitor of acyl coenzyme A:cholesterol acyltransferase, by liver microsomes in man
394 Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos. 2000 Sep;28(9):1069-76.
395 In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol. 2000 Oct;50(4):311-4.
396 Pharmacokinetic assessment of the sites of first-pass metabolism of BMS-181101, an antidepressant agent, in rats. J Pharm Pharmacol. 1998 Mar;50(3):275-8.
397 Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers. Br J Clin Pharmacol. 2001 Feb;51(2):164-8.
398 Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor. Eur J Clin Pharmacol. 1993;45(3):265-9.
399 Antidepressants: Past, Present and Future. Edited by Sheldon H. Preskorn Christina Y. Stanga John P. Feighner Ruth Ross. Page: 574.
400 Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun. 1998 Aug 28;249(3):838-43.
401 Proof of a 1-(3-chlorophenyl)piperazine (mCPP) intake: use as adulterant of cocaine resulting in drug-drug interactions? J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Aug 15;855(2):127-33.
402 Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica. 2003 Oct;33(10):989-98.
403 N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs. Cancer Chemother Pharmacol. 2000;45(4):298-304.
404 Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther. 2013 Feb;344(2):388-96.
405 Metabolism of ipecac alkaloids cephaeline and emetine by human hepatic microsomal cytochrome P450s, and their inhibitory effects on P450 enzyme activities. Biol Pharm Bull. 2001 Jun;24(6):678-82.
406 A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine--application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition. J Pharm Biomed Anal. 2002 Aug 22;30(1):113-24.
407 Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo. Mol Pharmacol. 2015 Apr;87(4):733-9.
408 Studies on the metabolism of the fentanyl-derived designer drug butyrfentanyl in human in vitro liver preparations and authentic human samples using liquid chromatography-high resolution mass spectrometry (LC-HRMS). Drug Test Anal. 2017 Jul;9(7):1085-1092.
409 The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers
410 Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol. 1997 Jun 1;53(11):1605-12.
411 Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos. 1996 Apr;24(4):487-94.
412 A cytochrome P450 class I electron transfer system from Novosphingobium aromaticivorans. Appl Microbiol Biotechnol. 2010 Mar;86(1):163-75.
413 Study on the cytochrome P450-mediated oxidative metabolism of the terpene alcohol linalool: indication of biological epoxidation
414 Metabolism of geraniol and linalool in the rat and effects on liver and lung microsomal enzymes
415 Metabolism of methoxyphenamine and 2-methoxyamphetamine in P4502D6-transfected cells and cell preparations. Xenobiotica. 1995 Sep;25(9):895-906.
416 Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42.
417 Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab. 2010 Oct;11(8):659-66.
418 [Trazodon--the antidepressant: mechanism of action and its position in the treatment of depression]. Psychiatr Pol. 2011 Jul-Aug;45(4):611-25.
419 Evaluation of interethnic differences in repinotan pharmacokinetics by using population approach. Drug Metab Pharmacokinet. 2006 Feb;21(1):61-9.
420 Cytochrome P450 inactivation by pharmaceuticals and phytochemicals: therapeutic relevance Drug Metab Rev. 2008;40(1):101-47. doi: 10.1080/03602530701836704.
421 Acetaminophen, via its reactive metabolite N-acetyl-p-benzo-quinoneimine and transient receptor potential ankyrin-1 stimulation, causes neurogenic inflammation in the airways and other tissues in rodents FASEB J. 2010 Dec;24(12):4904-16. doi: 10.1096/fj.10-162438.
422 Rapid detection and quantification of paracetamol and its major metabolites using surface enhanced Raman scattering. Analyst. 2023 Apr 11;148(8):1805-1814. doi: 10.1039/d3an00249g.
423 DrugBank(Pharmacology-Metabolism):Almogran
424 Cytochromes P450: a structure-based summary of biotransformations using representative substrates Drug Metab Rev. 2008;40(1):1-100. doi: 10.1080/03602530802309742.
425 CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies
426 Amitriptyline Therapy and CYP2D6 and CYP2C19 Genotype
427 Addition of amoxapine improves positive and negative symptoms in a patient with schizophrenia. Ther Adv Psychopharmacol. 2013 Dec;3(6):340-2.
428 DrugBank(Pharmacology-Metabolism)Amoxapine
429 A simplified procedure for the analysis of formoterol in human urine by liquid chromatography-electrospray tandem mass spectrometry: application to the characterization of the metabolic profile and stability of formoterol in urine
430 Mass balance and metabolism of [(3)H]Formoterol in healthy men after combined i.v. and oral administration-mimicking inhalation Drug Metab Dispos. 1999 Oct;27(10):1104-16.
431 Current pharmacogenomic recommendations in chronic respiratory diseases: Is there a biomarker ready for clinical implementation?
432 Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia J Clin Psychopharmacol. 2017 Jun;37(3):289-295. doi: 10.1097/JCP.0000000000000691.
433 Biological conversion of?aripiprazole lauroxil - An N-acyloxymethyl aripiprazole prodrug Results Pharma Sci. 2014 May 2;4:19-25. doi: 10.1016/j.rinphs.2014.04.002.
434 Effects of arotinolol, an alpha- and beta-adrenoceptor antagonist, on renin release from rat kidney cortical slices
435 Metabolism of atenolol in man. Xenobiotica. 1978 May;8(5):313-20.
436 DrugBank : Atenolol
437 Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism
438 The metabolism of berberine and its contribution to the pharmacological effects
439 Transformation of berberine to its demethylated metabolites by the CYP51 enzyme in the gut microbiota
440 Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 1998;63(13):1097-108.
441 Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection Drug Metab Dispos. 2006 Mar;34(3):427-39. doi: 10.1124/dmd.105.007617.
442 Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans
443 DrugBank(Pharmacology-Metabolism):Deucravacitinib
444 U. S. FDA Label -BNP-1350
445 Metabolic pathway of icotinib in vitro: the differential roles of CYP3A4, CYP3A5, and CYP1A2 on potential pharmacokinetic drug-drug interaction. J Pharm Sci. 2018 Apr;107(4):979-983.
446 Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human. Xenobiotica. 2021 May;51(5):590-604. doi: 10.1080/00498254.2021.1890275.
447 Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
448 Metabolic disposition of 14C-bromfenac in healthy male volunteers J Clin Pharmacol. 1998 Aug;38(8):744-52. doi: 10.1002/j.1552-4604.1998.tb04815.x.
449 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J Pharmacol Exp Ther. 2002 Jun;301(3):1025-32.
450 In Vitro Interaction of AB-FUBINACA with Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes and Drug Transporters
451 Structural elucidation of phase I and II metabolites of bupivacaine in horse urine and fungi of the Cunninghamella species using liquid chromatography/multi-stage mass spectrometry Rapid Commun Mass Spectrom. 2012 Jun 15;26(11):1338-46. doi: 10.1002/rcm.6225.
452 Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6). Eur J Clin Pharmacol. 1993;45(3):261-4.
453 DrugBank(Pharmacology-Metabolism)Buspirone
454 Metabolism of butyrylfentanyl in fresh human hepatocytes: chemical synthesis of authentic metabolite standards for definitive identification. Biol Pharm Bull. 2019;42(4):623-630.
455 Benzydamine N-oxygenation as an index for flavin-containing monooxygenase activity and benzydamine N-demethylation by cytochrome P450 enzymes in liver microsomes from rats, dogs, monkeys, and humans
456 Metabolism of carvedilol in dogs, rats, and mice Drug Metab Dispos. 1998 Oct;26(10):958-69.
457 The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
458 Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012 Apr;22(4):310-8.
459 Identification of human drug-metabolizing enzymes involved in the metabolism of SNI-2011. Biol Pharm Bull. 2001 Nov;24(11):1263-6.
460 Determination of the new monoamine oxidase inhibitor brofaromine and its major metabolite in biological material by gas chromatography with electron-capture detection
461 Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements Clin Pharmacokinet. 1996 Oct;31(4):257-74. doi: 10.2165/00003088-199631040-00003.
462 Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003 Aug;26(8):631-7.
463 Metabolism of chlorpheniramine in rat and human by use of stable isotopes Xenobiotica. 1991 Jan;21(1):97-109. doi: 10.3109/00498259109039454.
464 Classics in Chemical Neuroscience: Chlorpromazine ACS Chem Neurosci. 2019 Jan 16;10(1):79-88. doi: 10.1021/acschemneuro.8b00258.
465 Determination of chlorpromazine and its metabolites in animal-derived foods using QuEChERS-based extraction, EMR-Lipid cleanup, and UHPLC-Q-Orbitrap MS analysis. Food Chem. 2023 Mar 1;403:134298. doi: 10.1016/j.foodchem.2022.134298.
466 In Vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices Biopharm Drug Dispos. 2006 May;27(4):197-207. doi: 10.1002/bdd.500.
467 PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011 Nov;21(11):769-72.
468 Analytical methodologies for the enantiodetermination of citalopram and its metabolites
469 Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride
470 Determination of clomipramine or imipramine and their mono-demethylated metabolites in human blood or plasma by high-performance liquid chromatography
471 Metabolism of clomipramine in a Japanese psychiatric population: hydroxylation, desmethylation, and glucuronidation
472 Biotransformation of cobicistat: metabolic pathways and enzymes. Drug Metab Lett. 2016;10(2):111-23.
473 Pharmacogenetics of analgesic drugs
474 Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy
475 Dacomitinib: an investigational drug for the treatment of glioblastoma Expert Opin Investig Drugs. 2018 Oct;27(10):823-829. doi: 10.1080/13543784.2018.1528225.
476 In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans Drug Metab Dispos. 2010 Mar;38(3):405-14. doi: 10.1124/dmd.109.029165.
477 Characterization of Phase I Hepatic Metabolites of Anti-Premature Ejaculation Drug Dapoxetine by UHPLC-ESI-Q-TOF
478 Effects of Evodiamine on the Pharmacokinetics of Dapoxetine and Its Metabolite Desmethyl Dapoxetine in Rats
479 Effects of 22 novel CYP2D6 variants found in Chinese population on the metabolism of dapoxetine
480 Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside Biochem Pharmacol. 1983 Apr 1;32(7):1327-8. doi: 10.1016/0006-2952(83)90293-9.
481 Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo. Drug Metab Dispos. 2015 Aug;43(8):1267-76.
482 Clinical pharmacokinetics of imipramine and desipramine
483 Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV-50717) Compared With Tetrabenazine in Healthy Volunteers Clin Transl Sci. 2020 Jul;13(4):707-717. doi: 10.1111/cts.12754.
484 Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices Clin Pharmacokinet. 2004;43(3):157-85. doi: 10.2165/00003088-200443030-00002.
485 LC-MS/MS analysis of dextromethorphan metabolism in human saliva and urine to determine CYP2D6 phenotype and individual variability in N-demethylation and glucuronidation J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Dec 25;813(1-2):217-25. doi: 10.1016/j.jchromb.2004.09.040.
486 Classics in Chemical Neuroscience: Dextromethorphan (DXM). ACS Chem Neurosci. 2023 Jun 21;14(12):2256-2270. doi: 10.1021/acschemneuro.3c00088.
487 CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement. Xenobiotica. 2004 Oct;34(10):875-87.
488 The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. Br J Clin Pharmacol. 1994 Sep;38(3):243-8.
489 Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing. Br J Clin Pharmacol. 1999 Sep;48(3):317-22.
490 Dihydrocodeine: safety concerns
491 Pharmacokinetics and metabolism of diltiazem in healthy males and females following a single oral dose Eur J Drug Metab Pharmacokinet. 1993 Apr-Jun;18(2):199-206. doi: 10.1007/BF03188796.
492 Desacetyl-diltiazem displays severalfold higher affinity to CYP2D6 compared with CYP3A4. Drug Metab Dispos. 2002 Jan;30(1):1-3.
493 Bioconcentration, metabolism and effects of diphenhydramine on behavioral and biochemical markers in crucian carp (Carassius auratus) Sci Total Environ. 2016 Feb 15;544:400-9. doi: 10.1016/j.scitotenv.2015.11.132.
494 Non-invasive skin sampling detects systemically administered drugs in humans. PLoS One. 2022 Jul 26;17(7):e0271794. doi: 10.1371/journal.pone.0271794.
495 DrugBank(Pharmacology-Metabolism):Doxepin hydrochloride
496 CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. Clin Cancer Res. 2007 May 15;13(10):2970-6.
497 #N/A
498 Disposition, profiling and identification of emixustat and its metabolites in humans
499 Oxidative metabolism of encainide: polymorphism, pharmacokinetics and clinical considerations
500 Simultaneous measurement of epinastine and its metabolite, 9,13b-dehydroepinastine, in human plasma by a newly developed ultra-performance liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies Biomed Chromatogr. 2020 Sep;34(9):e4848. doi: 10.1002/bmc.4848.
501 Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor Xenobiotica. 2021 Feb;51(2):177-193. doi: 10.1080/00498254.2020.1821123.
502 Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram Drug Metab Dispos. 2001 Aug;29(8):1102-9.
503 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
504 Aniline and its metabolites generate free radicals in yeast
505 Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers
506 U. S. FDA Label -Fenfluramine
507 Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron J Clin Pharmacol. 2019 Nov;59(11):1505-1518. doi: 10.1002/jcph.1438.
508 LABEL:FESOTERODINE FUMARATE tablet, extended release
509 Identification and characterization of in vitro and in vivo fidarestat metabolites: Toxicity and efficacy evaluation of metabolites
510 Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism. Br J Clin Pharmacol. 2009 Jul;68(1):89-96.
511 Flibanserin therapy and CYP2C19 genotype.
512 Simultaneous identification and quantitation of fluoxetine and its metabolite, norfluoxetine, in biological samples by GC-MS
513 Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes. Basic Clin Pharmacol Toxicol. 2009 Nov;105(5):327-32.
514 Metabolism and transport of oxazaphosphorines and the clinical implications Drug Metab Rev. 2005;37(4):611-703. doi: 10.1080/03602530500364023.
515 Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma Cancer. 2007 Jun 1;109(11):2315-22. doi: 10.1002/cncr.22669.
516 Esophageal bezoar due to karaya gum granules used as a laxative
517 Incarceration of the medial collateral ligament in the intercondylar notch following proximal avulsion
518 A simple and rapid infrared-assisted self enzymolysis extraction method for total flavonoid aglycones extraction from Scutellariae Radix and mechanism exploration
519 Management of postoperative junctional ectopic tachycardia in pediatric patients: a survey of 30 centers in Germany, Austria, and Switzerland
520 Identification and determination of opipramol metabolites in plasma and urine
521 The metabolism and excretion of galantamine in rats, dogs, and humans Drug Metab Dispos. 2002 May;30(5):553-63. doi: 10.1124/dmd.30.5.553.
522 Ganaxolone
523 Contribution of cytochrome P450 isoforms to gliquidone metabolism in rats and human
524 Pharmacology, toxicology and clinical safety of glycopyrrolate
525 Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. Biochem Pharmacol. 2010 Oct 15;80(8):1252-9.
526 Update on hydrocodone metabolites in rats and dogs aided with a semi-automatic software for metabolite identification Mass-MetaSite
527 DrugBank(Pharmacology-Metabolism):Hydrocodone bitartrate
528 The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects
529 Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1551-64.
530 Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism
531 Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes
532 In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1
533 The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine
534 Comparative Pharmacokinetics and Safety of Imrecoxib, a Novel Selective Cyclooxygenase-2 Inhibitor, in Elderly Healthy Subjects. Drug Des Devel Ther. 2022 Nov 8;16:3865-3876. doi: 10.2147/DDDT.S387508.
535 In vitro metabolism of indiplon and an assessment of its drug interaction potential
536 Biotransformation of the ipecac alkaloids cephaeline and emetine from ipecac syrup in rats Eur J Drug Metab Pharmacokinet. 2002 Jan-Mar;27(1):29-35. doi: 10.1007/BF03190402.
537 The role of levomilnacipran in the management of major depressive disorder: a comprehensive review. Curr Neuropharmacol. 2016;14(2):191-9.
538 Advances in high-resolution MS and hepatocyte models solve a long-standing metabolism challenge: the loratadine story. Bioanalysis. 2016 Aug;8(16):1645-62.
539 In vitro metabolism of perospirone in rat, monkey and human liver microsomes
540 The wide variability of perospirone metabolism and the effect of perospirone on prolactin in psychiatric patients
541 Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats
542 Drugs of abuse in a non-conventional sample; detection of methamphetamine and its main metabolite, amphetamine in abusers' clothes by HPLC with UV and fluorescence detection
543 Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence
544 Effects of methamphetamine and its primary human metabolite, p-hydroxymethamphetamine, on the development of the Australian blowfly Calliphora stygia
545 Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics
546 Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine
547 Identification of novel metoclopramide metabolites in humans: in vitro and in vivo studies
548 The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos. 2002 Mar;30(3):336-43.
549 Lessons from pharmacogenetics and metoclopramide: toward the right dose of the right drug for the right patient. J Clin Gastroenterol. 2012 Jul;46(6):437-9.
550 DrugBank(Pharmacology-Metabolism):Metoprolol succinate
551 Metabolism of metoprolol in the rat in vitro and in vivo
552 Involvement of CYP1A2 in mexiletine metabolism. Br J Clin Pharmacol. 1998 Jul;46(1):55-62.
553 The in vitro metabolism of desglymidodrine, an active metabolite of prodrug midodrine by human liver microsomes
554 The biotransformation of [14C]minaprine in man and five animals species Xenobiotica. 1981 Nov;11(11):735-47. doi: 10.3109/00498258109045877.
555 Clinical pharmacokinetics of mirtazapine
556 The pharmacokinetics of bucindolol and its major metabolite in essential hypertension
557 Population pharmacokinetic modeling of motesanib and its active metabolite, M4, in cancer patients
558 DrugBank(Pharmacology-Metabolism):Adagrasib
559 Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro. J Pharm Pharmacol. 2014 Nov;66(11):1534-51.
560 Characterization of Ca(2+)-antagonistic effects of three metabolites of the new antihypertensive agent naftopidil, (naphthyl)hydroxy-naftopidil, (phenyl)hydroxy-naftopidil, and O-desmethyl-naftopidil J Cardiovasc Pharmacol. 1991 Dec;18(6):918-25. doi: 10.1097/00005344-199112000-00020.
561 Evaluation of 24 CYP2D6 variants on the metabolism of nebivolol in vitro. Drug Metab Dispos. 2016 Nov;44(11):1828-1831.
562 Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery
563 Disposition and biotransformation of the antiretroviral drug nevirapine in humans Drug Metab Dispos. 1999 Aug;27(8):895-901.
564 Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions J Antimicrob Chemother. 2014 Feb;69(2):476-82. doi: 10.1093/jac/dkt359.
565 Sulfation of 12-hydroxy-nevirapine by human SULTs and the effects of genetic polymorphisms of SULT1A1 and SULT2A1. Biochem Pharmacol. 2022 Oct;204:115243. doi: 10.1016/j.bcp.2022.115243.
566 U. S. FDA Label -Nevirapine
567 Assay of nicergoline and three metabolites in human plasma and urine by high-performance liquid chromatography-atmospheric pressure ionization mass spectrometry J Chromatogr. 1991 Aug 23;568(2):375-84. doi: 10.1016/0378-4347(91)80175-c.
568 Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes Clin Pharmacol Ther. 1998 Oct;64(4):384-90. doi: 10.1016/S0009-9236(98)90069-8.
569 Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline J Clin Pharmacol. 2019 Apr;59(4):532-540. doi: 10.1002/jcph.1344.
570 DrugBank(Pharmacology-Metabolism)Nortriptyline hydrochloride
571 Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93.
572 The Unique Human N10-Glucuronidated Metabolite Formation from Olanzapine in Chimeric NOG-TKm30 Mice with Humanized Livers. Drug Metab Dispos. 2023 Apr;51(4):480-491. doi: 10.1124/dmd.122.001102.
573 Quantification of olanzapine and its three metabolites by liquid chromatography-tandem mass spectrometry in human body fluids obtained from four deceased, and confirmation of the reduction from olanzapine N-oxide to olanzapine in whole blood in vitro. Forensic Toxicol. 2023 Jul;41(2):318-328. doi: 10.1007/s11419-023-00662-0.
574 Identification of novel ondansetron metabolites using LC/MS(n) and NMR J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Sep 15;1095:138-141. doi: 10.1016/j.jchromb.2018.07.013.
575 Human cytochromes mediating gepirone biotransformation at low substrate concentrations. Biopharm Drug Dispos. 2003 Mar;24(2):87-94.
576 Metabolism and Disposition of Prescription Opioids: A Review
577 Zhx2 Is a Candidate Gene Underlying Oxymorphone Metabolite Brain Concentration Associated with State-Dependent Oxycodone Reward. J Pharmacol Exp Ther. 2022 Aug;382(2):167-180. doi: 10.1124/jpet.122.001217.
578 Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests. Pharmacogenomics J. 2022 Feb;22(1):25-32. doi: 10.1038/s41397-021-00253-5.
579 Association of CYP2D6 genotype predicted phenotypes with oxycodone requirements and side effects in children undergoing surgery. Ann Transl Med. 2022 Dec;10(23):1262. doi: 10.21037/atm-2022-58.
580 Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8.
581 S73 | METXBIODB | metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
582 Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers Biopharm Drug Dispos. 2004 Nov;25(8):329-37. doi: 10.1002/bdd.410.
583 Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos. 2010 Mar;38(3):376-85.
584 Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35.
585 Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer Xenobiotica. 2013 May;43(5):443-53. doi: 10.3109/00498254.2012.734642.
586 Anti-Parkinson's disease drugs and pharmacogenetic considerations Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):859-74. doi: 10.1517/17425255.2013.789018.
587 DrugBank(Pharmacology-Metabolism)Phenacetin
588 The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites Drug Metab Dispos. 2020 Nov;48(11):1113-1120. doi: 10.1124/dmd.120.000188.
589 Hazardous Substances Data Bank:Piperazine
590 Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: similarities and difference in the metabolism of pitavastatin in monkeys and humans
591 FDA Center for Drug Evaluation and Research: Pitolisant Non-clinical Review(s)
592 Wakix, INN-Pitolisant - European Medicines Agency - Europa EU
593 Absorption, metabolism, and excretion of [(14)C]ponatinib after a single oral dose in humans Cancer Chemother Pharmacol. 2017 Mar;79(3):507-518. doi: 10.1007/s00280-017-3240-x.
594 In vitro metabolites characterization of ponatinib in human liver microsomes using ultra-high performance liquid chromatography combined with Q-Exactive-Orbitrap tandem mass spectrometry Biomed Chromatogr. 2020 Jun;34(6):e4819. doi: 10.1002/bmc.4819.
595 Quantitative analysis of primaquine and its metabolites in human urine using liquid chromatography coupled with tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Dec 15;1213:123517. doi: 10.1016/j.jchromb.2022.123517.
596 Enantioselective metabolism of primaquine by human CYP2D6 Malar J. 2014 Dec 17;13:507. doi: 10.1186/1475-2875-13-507.
597 Metabolites of procainamide and practolol inhibit complement components C3 and C4 Biochem J. 1988 Apr 15;251(2):323-6. doi: 10.1042/bj2510323.
598 Influence of cytochrome P450 genotype on the plasma disposition of prochlorperazine metabolites and their relationships with clinical responses in cancer patients Ann Clin Biochem. 2018 May;55(3):385-393. doi: 10.1177/0004563217731432.
599 Simultaneous determination of prochlorperazine and its metabolites in human plasma using isocratic liquid chromatography tandem mass spectrometry Biomed Chromatogr. 2012 Jun;26(6):754-60. doi: 10.1002/bmc.1725.
600 Bioavailability and metabolism of prochlorperazine administered via the buccal and oral delivery route J Clin Pharmacol. 2005 Dec;45(12):1383-90. doi: 10.1177/0091270005281044.
601 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
602 An HPLC-ESI-MS method for simultaneous determination of fourteen metabolites of promethazine and caffeine and its application to pharmacokinetic study of the combination therapy against motion sickness J Pharm Biomed Anal. 2012 Mar 25;62:119-28. doi: 10.1016/j.jpba.2011.12.033.
603 A liquid chromatographic method for the simultaneous determination of promethazine and three of its metabolites in plasma using electrochemical and UV detectors J Chromatogr Sci. 2001 Feb;39(2):70-2. doi: 10.1093/chromsci/39.2.70.
604 CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. Pharmacogenetics. 1996 Oct;6(5):449-57.
605 A rapid HPLC assay for the simultaneous determination of propafenone and its major metabolites in human serum Anal Sci. 2004 Sep;20(9):1307-11. doi: 10.2116/analsci.20.1307.
606 Isolation, purification, and structure identification of glucuronic acid conjugates of propranolol and alprenolol and their ring-hydroxylated metabolites Drug Metab Dispos. 1984 Nov-Dec;12(6):749-54.
607 Rapid and simultaneous extraction of propranolol, its neutral and basic metabolites from plasma and assay by high-performance liquid chromatography J Chromatogr. 1985 Oct 11;343(2):349-58. doi: 10.1016/s0378-4347(00)84603-4.
608 Poncirin and its metabolite ponciretin attenuate colitis in mice by inhibiting LPS binding on TLR4 of macrophages and correcting Th17/Treg imbalance
609 Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos. 2009 Feb;37(2):254-8.
610 Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro. Drug Metab Dispos. 2012 Sep;40(9):1778-84.
611 CYP450 phenotyping and metabolite identification of quinine by accurate mass UPLC-MS analysis: a possible metabolic link to blackwater fever
612 Netupitant PET imaging and ADME studies in humans
613 Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions
614 Fatal, Intentional Overdose of Ranolazine: Post-Mortem Distribution of Parent Drug and its Major Metabolite
615 Comparison of pharmacokinetic parameters of ranolazine between diabetic and non-diabetic rats
616 Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor
617 LABEL:Risperidone
618 Biotransformation of moclobemide in humans
619 Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment. Cancer Chemother Pharmacol. 2021 Aug;88(2):259-270. doi: 10.1007/s00280-021-04278-2.
620 Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett. 2011 Dec;5(4):280-9.
621 A Phase 1 Study to Evaluate Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Savolitinib in Healthy Male Volunteers
622 Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos. 2003 Sep;31(9):1093-102.
623 Metabolism of sertindole: identification of the metabolites in the rat and dog, and species comparison of liver microsomal metabolism
624 Sertindole : a review of its use in schizophrenia
625 Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70.
626 Pharmacogenetic Testing and Therapeutic Drug Monitoring Of Sertraline at a Residential Treatment Center for Children and Adolescents: A Pilot Study. Innov Pharm. 2022 Dec 26;13(4):10.24926/iip.v13i4.5035. doi: 10.24926/iip.v13i4.5035.
627 Sertraline. 2022 May 15. Drugs and Lactation Database (LactMed?) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006C.
628 Neonicotinoids and pharmaceuticals in hair of the Red fox (Vulpes vulpes) from the Cavallino-Treporti peninsula, Italy. Environ Res. 2023 Jul 1;228:115837. doi: 10.1016/j.envres.2023.115837.
629 Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism
630 Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation. Biol Pharm Bull. 2015;38(1):58-65.
631 The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90.
632 Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53 Suppl 1(Suppl 1):5S-12S. doi: 10.1046/j.0306-5251.2001.00027.x.
633 Erectile dysfunction drugs changed the protein expressions and activities of drug-metabolising enzymes in the liver of male rats. Oxid Med Cell Longev. 2016;2016:4970906.
634 Regioselectivity and stereoselectivity of the metabolism of the chiral quinolizidine alkaloids sparteine and pachycarpine in the rat
635 Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial Malar J. 2016 Feb 18;15:97. doi: 10.1186/s12936-016-1145-5.
636 PharmGKB:Tamoxifen citrate
637 Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
638 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
639 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
640 Identification and biological activity of tamoxifen metabolites in human serum Biochem Pharmacol. 1983 Jul 1;32(13):2045-52. doi: 10.1016/0006-2952(83)90425-2.
641 PharmGKB summary: tamoxifen pathway, pharmacokinetics Pharmacogenet Genomics. 2013 Nov;23(11):643-7. doi: 10.1097/FPC.0b013e3283656bc1.
642 The tamoxifen dilemma. Carcinogenesis. 1999 Jul;20(7):1153-60.
643 Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans Drug Metab Dispos. 1998 Mar;26(3):240-5.
644 Absorption, metabolism and excretion of tamsulosin hydrochloride in man Xenobiotica. 1996 Jun;26(6):637-45. doi: 10.3109/00498259609046739.
645 Simultaneous determination of tandospirone and its active metabolite, 1-[2-pyrimidyl]-piperazine in rat plasma by LC-MS/MS and its application to a pharmacokinetic study
646 Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. J Clin Pharmacol. 2015 Sep;55(9):1004-11.
647 DrugBank(Pharmacology-Metabolism):Tetrabenazine
648 Extraction of structure-activity relationship information from high-throughput screening data Curr Med Chem. 2009;16(31):4049-57. doi: 10.2174/092986709789378189.
649 Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metab Dispos. 2007 Jul;35(7):1135-41.
650 Metabolism of ophthalmic timolol: new aspects of an old drug. Basic Clin Pharmacol Toxicol. 2011 May;108(5):297-303.
651 Quantitative determination of pentazocine in plasma and of pentazocine and metabolites in urine
652 Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May;38(5):871-8.
653 Trends in Tramadol: Pharmacology, Metabolism, and Misuse Anesth Analg. 2017 Jan;124(1):44-51. doi: 10.1213/ANE.0000000000001683.
654 Simultaneous LC-MS/MS quantification of oxycodone, tramadol and fentanyl and their metabolites (noroxycodone, oxymorphone, O- desmethyltramadol, N- desmethyltramadol, and norfentanyl) in human plasma and whole blood collected via venepuncture and volumetric absorptive micro sampling. J Pharm Biomed Anal. 2021 Sep 5;203:114171. doi: 10.1016/j.jpba.2021.114171.
655 Total determination of triclabendazole and its metabolites in bovine tissues using liquid chromatography-tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 1;1109:54-59. doi: 10.1016/j.jchromb.2019.01.021.
656 Egaten FDA label
657 In Vitro Hepatic Oxidative Biotransformation of Trimethoprim Drug Metab Dispos. 2015 Sep;43(9):1372-80. doi: 10.1124/dmd.115.065193.
658 Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996 May;24(5):602-9.
659 The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos. 1994 Mar-Apr;22(2):269-74.
660 Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans
661 The Utilization of Mu-Opioid Receptor Biased Agonists: Oliceridine, an Opioid Analgesic with Reduced Adverse Effects
662 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW: Umeclidinium Bromide
663 LABEL:INVOQ- upadacitinib tablet, extended release
664 O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999 May;20(5):480-90.
665 Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 1996 Feb;41(2):149-56.
666 Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers
667 Accidental intoxications in toddlers: lack of cross-reactivity of vilazodone and its urinary metabolite M17 with drug of abuse screening immunoassays
668 DETERMINATION OF VENLAFAXINE, VILAZODONE AND THEIR MAIN ACTIVE METABOLITES IN HUMAN SERUM BY HPLC-DAD AND HPLC-MS
669 Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018 Jun;57(6):673-686.
670 Metabolism of a potential 8-aminoquinoline antileishmanial drug in rat liver microsomes
671 Zolpidem urine excretion profiles and cross-reactivity with ELISA(?) kits in subjects using Zolpidem or Ambien(?) CR as a prescription sleep aid

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.